



Commission of the European Communities

# **food – science and techniques**

## **Reports of the Scientific Committee for Food**

(Twenty-second series)



**Report**

EUR 12535 EN



Commission of the European Communities

# food – science and techniques

## Reports of the Scientific Committee for Food

(Twenty-second series)

Directorate-General  
Internal Market and Industrial Affairs



Published by the  
**COMMISSION OF THE EUROPEAN COMMUNITIES**  
Directorate-General  
Telecommunications, Information Industries and Innovation  
L-2920 Luxembourg

#### **LEGAL NOTICE**

Neither the Commission of the European Communities nor any person acting on behalf of the Commission is responsible for the use which might be made of the following information.

This publication can also be found in the following languages:

ES	ISBN 92-826-1066-7
DA	ISBN 92-826-1067-5
DE	ISBN 92-826-1068-3
GR	ISBN 92-826-1069-1
FR	ISBN 92-826-1071-3
IT	ISBN 92-826-1072-1
NL	ISBN 92-826-1073-X
PT	ISBN 92-826-1074-8

Cataloguing data can be found at the end of this publication

Luxembourg: Office for Official Publications of the European Communities, 1990  
ISBN 92-826-1070-5

Catalogue number: CD-NA-12535-EN-C

© ECSC-EEC-EAEC, Brussels · Luxembourg, 1990

*Printed in Belgium*

# C O N T E N T S

Page

## REPORT OF THE SCIENTIFIC COMMITTEE FOR FOOD ON :

Antioxidants .....	1
(Opinion expressed 11 December 1987)	
TERMS OF REFERENCE .....	1
BACKGROUND .....	1
MECHANISMS OF OXIDATION .....	2
ACTION OF ANTIOXIDANTS IN FATS AND OILS .....	4
SYNERGISM .....	5
NEED FOR ANTIOXIDANTS .....	6
LEVEL OF USE; DAILY INTAKE .....	7
NUTRITIONAL IMPLICATIONS RELATING TO POLYUNSATURATED FATS AND OILS .	8
TOXICOLOGICAL EVALUATION .....	8
ANNEXES .....	11
REFERENCES .....	25

Composition of the Scientific Committee for Food

Members :

J. Carballo		(from 1 April 1987)
A. Carere		(from 7 April 1988)
G. Elton	(Vice-Chairman)	
M. Ferreira		
M. Gibney		(from 1 April 1987)
A. Hildebrandt	(Vice-Chairman)	(to 7 April 1988)
I. Krudsen		(from 7 April 1988)
A. Mariani		
K. Netter		
A. Noirfalise		
G. Pascal		
J. Ponz-Marin		(from 1 April 1987)
J. Rey		
V. Silano	(Chairman)	(to 7 April 1988)
A. Somogyi		(from 7 April 1988)
J. Steadman		
A. Trichopoulou		
C. van der Heijden	(Chairman)	
R. Wennig	(Vice-Chairman)	

Consultores emeriti :

P. Elias  
A. Lafontaine  
E. Poulsen  
R. Truhaut  
C. van Esch

## Report of the Scientific Committee for Food on Antioxidants

(Opinion expressed 11 December 1987)

### TERMS OF REFERENCE

To review the available data on the safety of antioxidants.

### BACKGROUND

The Committee has carried out ad hoc reviews of the safety of a number of antioxidants over a period of time:

- gallates, 2 July 1976;
- tertiary butylhydroquinone (TBHQ) (unpublished);
- butylated hydroxyanisole (BHA), 29 April 1983;
- erythorbic acid (unpublished).

Following these evaluations, and particularly that of BHA, the Committee recommended that the safety of other antioxidants should also be assessed. This review became more pressing with the disclosure in 1983 of suspected adverse effects of butylated hydroxytoluene (BHT) in rats, and the Commission decided that the Committee should undertake a complete revision of a number of substances listed as antioxidants in the Directive on Antioxidants.

This view was undertaken up to March 1986 and the results made known to interested parties. In the meantime new data have become available, and prior to publication of the report the Committee (reconstituted in April 1986) has been asked to advise on whether these new data would affect the conclusions drawn in 1986.

The Committee believes that it would be premature to undertake a further major review at this time as clarification of a number of outstanding questions, particularly on BHA, is expected to become available during the next two to three years. At that time, or sooner, if the data are such as to warrant more immediate change, the Committee would wish to undertake a further comprehensive review of the safety of antioxidants. In the meantime the earlier conclusions remain valid.

The substances included in the review are :

L-ascorbic acid (E 300);  
Sodium L-ascorbate (E 301);  
Calcium L-ascorbate (E 302);  
Ascorbyl palmitate (E 304);  
Tocopherol extracts (E 306);  
Alpha-tocopherol (E 307);  
Gamma-tocopherol (E 308);  
Delta-tocopherol (E 309);  
Propyl gallate (E 310);  
Octyl gallate (E 311);  
Dodecyl gallate (E 312);  
Butylated hydroxyanisole (E 320)  
and Butylated hydroxytoluene (E 321).

Data were also provided on the antioxidants :

and Tertiary butylhydroquinone (TBHQ)  
Erythorbic acid.

The Committee was assisted in its review by documentation provided by the Confederation of the Food and Drinks Industries of the EEC on the mode of action of antioxidants, the need for their use and possible hazards in the absence of antioxidants. Information on current national legislation reflecting current usage patterns was provided from the Commission files.

Committee members participated in an ad hoc working group of experts on antioxidants which took place 25, 26 October 1984.

Many toxicological data available only in summary form to the ad hoc working group were presented to the Committee during the present review. The main sources of toxicological data are referenced.


### MECHANISMS OF OXIDATION

Unsaturated fatty acids are peroxidised in the presence of molecular oxygen by a three-step reaction involving free radical initiation, propagation and finally the appearance of secondary products (terminal process).

In the initiation step, the unsaturated lipid (LH) is converted via hydrogen abstraction into a lipid free radical L. in a process catalysed by light, heat or traces of transition metals. This carbon-centered radical is oxidised by molecular oxygen to a lipid peroxy radical LOO. which is capable of participating in the initiation process by abstracting



hydrogen from another lipid molecule (LH) thus leading to propagation of the oxidation reaction. The lipid hydroperoxide formed by hydrogen donation to the peroxy radical decomposes by secondary reactions to a wide variety of monomeric and polymeric products the chemistry of which is not yet fully understood. In the terminal process, low molecular LO<sub>2</sub> which in turn will break down on heating or metal catalysis to various types of secondary products including aldehydes, ketones, alcohols, esters, alkyl radicals and short chain hydrocarbons.



Chain termination processes include :



the third of which is probably the most important at normal oxygen pressures.




Three essential objections to the presence of products of lipid peroxidation in food can be advanced :

1. A number of volatile secondary products give rise to off-odours and off-flavours which are not acceptable to the consumer.
2. The nutritional value of food may be decreased by the destruction of unsaturated fatty acids and of other essential food constituents possessing an unsaturated structure, e.g. Vitamin A.
3. Adverse health effects have been ascribed to the ingestion of lipid peroxidation products though this topic has not been extensively studied. It is, however, clear that :

- (a) certain peroxidation products such as malonaldehyde and hydroperoxy derivatives of methyl linoleate and methyl linolenate are mutagens and that
- (b) Lipid peroxidation induced in vivo is associated with detrimental disturbances of membrane integrity and function. Rancidity itself may limit the intake of lipid peroxides.

### ACTION OF ANTIOXIDANTS IN FATS AND OILS

Phenolic antioxidants (AH) interfere with lipid peroxidation by reaction with the radicals formed :



Among these reactions, scavenging of the carbon-centered radical L. is assumed to be less efficient than scavenging of the oxygen-centered radicals, especially of the peroxy radical LOO.. By removal of LOO. the antioxidant has a chain-breaking action; this action is most powerful during the early induction period when peroxide accumulation proceeds slowly but will be less successful once considerable peroxide levels have been achieved. At elevated temperatures when peroxide formation is accelerated optimal antioxidant concentrations are higher than those at room temperature.

Antioxidants are themselves converted into radical species during their inhibitory action on lipid peroxidation. These phenoxyl radicals A. undergo a variety of reactions :

1. The radical can be further oxidised to yield a stable quinone.
2. The parent antioxidant can be regenerated by reducing agents; this is a fundamental mechanism of synergism between individual antioxidants (see below).
3. Dimerisation can take place, and oligomers can also be formed.
4. The radical can form adducts with lipid peroxy radicals to yield various non-radical species.

The fate of antioxidant-derived phenoxyl radicals has been studied in model systems using well-defined substrates such as a specific linoleic acid hydroperoxide or tert-butylhydroperoxide, and the structure of oligomers and adducts has been described. However, little is known about the fate of antioxidants in peroxidised fats and oils.

At very high antioxidant concentrations, the removal of the antioxidant-derived phenoxyl radicals by the processes listed above may be incomplete, and pro-oxidative effects of the remaining radicals may occur.

Optimum antioxidative concentrations at a given temperature do exist for phenolic antioxidants, notably tocopherols, which when exceeded result in decreased instead of increased stability of the fat or oil to be protected.

### SYNERGISM

Synergism can take place between two antioxidants or between an antioxidant and another type of compound. Two fundamental mechanisms of synergism can be described :

1. The synergist acts by regenerating the parent antioxidant molecule AH from the phenoxyl radical A. which has been formed by the protection process. The synergism between ascorbic acid, ascorbate or ascorbyl palmitate on the one hand and tocopherols on the other hand is commonly ascribed to such action. The action of Vitamin C compounds on peroxidising lipid may however not be restricted to such synergist effects; a scavenger effect on peroxy and alkoxy radicals has not been excluded. The synergism between BHA and BHT has been studied in a model system using the peroxy radical prepared from tert-butylhydroperoxide, and it was shown that the BHA phenoxyl radical accepts hydrogen from BHT to regenerate BHA while BHT itself is oxidised to the quinone methide.
2. Functional synergism is present between phenolic antioxidants and metal sequestering agents like citric acid, phosphoric acid or EDTA; the latter will decrease the concentration of free transition metal ions and thus remove highly active catalysts of the initiation process and of the hydro-peroxide decomposition process.

The present Council Directive on antioxidants in food contains a list of substances which enhance the antioxidant effect of primary antioxidants. The safety in use of these substances which may also fulfil other technological functions in food is presently being reviewed by the Committee.

Citric acid and phosphoric acid are particularly useful in vegetable oils, but not animal fats. This has been ascribed to the fact that, while vegetable fats contain significant quantities of tocopherols, animal fats usually contain very little. Hence the acids involved in this synergism cannot fulfil their function.

## NEED FOR ANTIOXIDANTS

Antioxidant technology is important in preserving edible fats, oils and lipid-containing food from development of objectionable flavours and odours, such as those resulting from oxidative rancidity and from formation of decomposition products which, as mentioned earlier, may be harmful. Furthermore, the nutritional quality of foodstuffs may be decreased by the oxidative loss of the fat soluble Vitamins A and E, or of unsaturated fatty acids. Antioxidants, to be effective, must be used with food materials of good quality. They will not protect (or mask) fat or fatty food which has already deteriorated from abusive storage or which was prepared from unsound raw materials. Best results can be expected only if the antioxidants are incorporated promptly into freshly-prepared products of good quality and if these products are subsequently packaged properly and stored under correct conditions.

The Committee was informed that antioxidants are used for a number of purposes. They can be of use in maintaining organoleptic quality by avoiding rancidity. There is economic benefit in the extension of the shelf-life of the foodstuff (this may be of significance for foodstuffs processed in one country and sold in other EEC countries or for foodstuffs of low consumption, for which a long shelf-life is desirable). As regards the technological benefits, very often the final processor of the foodstuff has to store an oil or fat used as an ingredient. These ingredients need protection during storage and before further processing can take place and the antioxidant has technological usefulness in maintaining the ingredient in good quality.

Information submitted to the Committee suggests the principal, but not exclusive, uses of antioxidants are to be found in the following groups of foodstuffs.

Vitamin preparations - preservation of vitamin content

Flavours ) - sensitive compounds, e.g. terpenes, aldehydes oxidize essential  
oils ) easily

Animal fats )  
Butter fat )  
Vegetable oils )

Shortenings ) - protection of the oil or fat component of the product

Biscuits )  
Crisps )  
Snack foods )  
Nuts )

Chewing gum ) - preservation of the unsaturated nature of the gum base; antioxidant remains in the base and is not normally ingested in significant quantities

Dried soups ) - protection of unsaturated fatty acids which give the characteristic flavour

Mayonnaise and emulsified sauces ) - protection of oil content during storage

Salted margarines ) - animal fat based margarines require additional antioxidant

Potato granules, flakes and powder ) - protection of unsaturated fatty acids; protection of the product during processing and storage

#### LEVEL OF USE; DAILY INTAKE

The Committee was provided with information on usage levels of antioxidants in food in the EEC Member States. This information showed considerable differences in usage patterns. It appears that these differences have been caused by a combination of several factors (e.g. special rules on the types of oil which might be used for specific purposes, availability of particular antioxidants, recipe traditions, distribution network). For similar reasons, only limited information was available to the Committee on interchangeability of antioxidants and the consequences that could ensue if the use of one or other substance were to be curtailed.

Nevertheless, the Committee was given estimates of possible total intake of antioxidants which varied from about 14 mg/person/day based on theoretical calculations to about 1 mg based on statistics on production and sale of antioxidants in the EEC.

Neither approach takes into account the losses of antioxidants during processing. This varies according to the foodstuff in question and the antioxidant concerned. In the case of phenolic antioxidants used in biscuits and snack foods (their main use), the figures for loss are said to be of the order of 35% and 50-90% respectively.

The daily intake (maximum) of BHA has been estimated to be 4 mg in the Netherlands. BHT and gallates were not detected in the foods examined.

The Committee emphasised the need for more extensive information on the daily intake of antioxidants, including knowledge of the intake of individual compounds.

## NUTRITIONAL IMPLICATIONS RELATING TO POLYUNSATURATED FATS AND OILS

This review is not concerned with the problems of diet or with consideration of the possible advantages or disadvantages of polyunsaturated fats in comparison with other fats. However, it should be noted that in the absence of antioxidants, the dietary level of polyunsaturated fats may fall.

## TOXICOLOGICAL EVALUATION

A summary of the evaluations is given in Annex 1.

The Committee's assessments of individual substances are contained in Annex 2. However, some general comments are pertinent.

Many reviews have appeared on the biological effects of lipid oxidation products and their relevance to cancer. Lipid oxidation products have been implicated in the disruption of biological membranes, the inactivation of enzymes and damage to proteins, the formation of age pigments in damaged cell membranes, oxidative damage to the lung by atmospheric pollutants, and in the causation of cancer. It is postulated that chemical carcinogenesis results from oxidation of chemical agents into reactive intermediates; and experimental studies in which antioxidants, such as BHA and BHT, have been shown to possess anti-carcinogenic properties have been interpreted as demonstrating beneficial effects of anti-oxidant activity in scavenging free radicals. However, this is probably of little relevance to the use of antioxidants as food additives where the intakes are small compared with those employed experimentally - and there is no evidence that such direct benefits to health (as might arise from prevention of in vivo auto-oxidation) results from the ingestion of food to which antioxidants have been added for important technological purposes. Nor is it clear the extent to which ingestion of foods which in the absence of added antioxidants could contain lipid oxidation products would alter the actual intake of such products or be likely to lead to adverse health effects. Rancidity itself may limit intake.

In assessing the safety 'in use' of individual antioxidants the Committee raised questions of wider toxicological principle. The results of recent carcinogenicity studies with BHA and BHT (together with data from subsequent research into specificity and mechanism of action of BHA) made it necessary to consider both the concept of a threshold for tumorigenesis (in the absence of evidence of genotoxicity) and whether effects in the rodent forestomach should be considered significant for prediction of effects on human health.

The Committee considered that if such tumour production is either irrelevant in the context of risk to the consumer, or capable of being dealt with in the same way as any other toxic effect with a demonstrable threshold, then the usual safety factor should be employed in using a NEL to establish an ADI. Furthermore, if the tumorigenic properties of BHA and BHT in rodents are not considered important as predictors of possible effects in humans then there should be no need to carry out strictly comparable types of

long-term/carcinogenicity studies with other phenolic antioxidants. Likewise, if the effects of BHA on the rodent forestomach are not considered relevant for man, then distinction between other antioxidants on the basis of their ability to produce hyperplasia in this organ should not be part of the assessment of their safety in use.

The Committee recognised that there was a threshold for the non-genotoxic tumorigenic effects of BHA and BHT. In the case of BHT, it was decided that since the NEL for tumorigenesis is higher than that for haemorrhagic and other toxic effects, the ADI should be based on these latter effects, with a standard safety factor of 100. It was not considered necessary to ask for carcinogenicity studies of similar design to be carried out on other phenolic antioxidants. With BHA, although the Committee thought the effects on the rodent forestomach were unlikely to be relevant for man (and were reassured by results from species without a forestomach) they did not feel able to dismiss the forestomach findings completely - and used the MEL for induction of hyperplasia in the rat forestomach as the basis for setting an ADI, without using a greater safety factor than usual. Whether there is a need for further studies of induction of forestomach hyperplasia by other antioxidants, will depend on the results of ongoing studies with BHA.

The Committee recommended that the Commission carry out regular reviews of the toxicology and levels of use/intake of the food additive antioxidants. This is to ensure that the intakes of BHA and BHT are indeed acceptable, and that any changing patterns of use, in the wake of recent concerns with BHA and BHT, do not result in any undesirable increase in the use/intake of other antioxidants, given the possible need to use proportionately larger amounts of other compounds to achieve the same technological effects.

In the case of ascorbic acid and tocopherols, the Committee did not think it appropriate to set an ADI for a vitamin present naturally in the diet at far higher levels than would be contributed by their use as antioxidants.





## ANNEXES



SUMMARY OF CONCLUSIONS

L-ascorbic acid	(E300)		
Sodium L-ascorbate	(E301)	Acceptable	
Calcium L-ascorbate	(E302)		
Ascorhyl palmitate	(E304)		
Isoascorbic acid (Erythorbic acid)		Not acceptable	
Tocopherol extracts	(E306)		
Alpha-tocopherol	(E307)	Acceptable	
Gamma-tocopherol	(E308)		
Delta-tocopherol	(E309)		
Propyl gallate	(E310)		
Octyl gallate	(E311)	Group ADI	0-0.5 mg/kg bw
Dodecyl gallate	(E312)		
Butylated hydroxyanisole	(E320)	Temporary ADI	0-0.5 mg/kg bw
Butylated hydroxytoluene	(E321)	ADI	0-0.05 mg/kg bw
Tertiary butylhydroquinone		Not acceptable	

ASSESSMENT OF INDIVIDUAL ANTIOXIDANTS

L-ascorbic acid, and its calcium and sodium salts

Ascorbic acid (Vitamin C) is present in many rapidly growing leafy vegetables, tomatoes, potatoes and fruits. Foods of animal origin are poor sources. Only L(+) ascorbic acid is used as a food additive.

Ascorbates are used as inhibitors of enzymatic browning, as antioxidants in a variety of foods and beverages.

Toxicological data from short-term, long-term, reproductive and teratogenicity studies were available and showed no evidence of adverse effects even at relatively high dosage (from 1-2 g/kg bw/d). Mutagenicity data show that ascorbic acid does not cause gene mutations and although *in vitro* tests suggest that it causes DNA strand breaks and chromosome damage, the limited *in vivo* data are negative. Ascorbic acid appears to be able to potentiate or inhibit the mutagenic effects of other chemicals.

Some studies in man indicated a diuretic effect at 5 mg/kg bw and glycosuria at 30-100 mg/kg bw - but these results were not confirmed in large scale, double blind studies. Daily therapeutic doses of the order of 100 mg/kg bw over a long period have not shown adverse effects.

It is estimated that the normal daily intake of ascorbic acid from natural sources is 30-100 mg. The Committee considered that the use of ascorbic acid and its calcium and sodium salts as food additives would represent only a very small fraction of the total dietary intake.

The Committee therefore decided it was inappropriate to establish an ADI for L-ascorbic acid and its calcium and sodium salts, which they found acceptable for food additive use.

## Ascorbyl palmitate

Ascorbyl palmitate is presumed to yield ascorbic acid during digestion.

Ascorbyl palmitate is used as an antioxidant in cooking fats. The commercial material tested was thought to have contained 5-20% ascorbyl stearate and 80-95% palmitate. The data would therefore be suitable for evaluating the stearate.

Toxicological data from short-term (up to nine months) and long-term studies were available in which no adverse effects were noted at 0.25% in the diet. The formation of bladder stones in a few animals in high dose groups was not thought to be relevant for man.

The Committee decided that ascorbyl palmitate was acceptable, with ascorbic acid and its salts, for food additive use.

## Isoascorbic acid - opinion expressed in September 1984

The Committee was asked to consider the safety in use in food of isoascorbic acid (erythorbic acid) as an antioxidant, particularly in meat products and in (imported) wines.

The Committee was informed that isoascorbic acid can be used in meat products for the same purposes as ascorbic acid, corresponding quantities having the same technological effect.

The use of isoascorbic acid in wine is not authorised at Community level but discussion has been taking place to amend these rules, at least as far as imports are concerned.

The Committee has not considered in detail the special problems that might exist for all salts of isoascorbic acid, but its opinion on the acid itself is valid also for the sodium, potassium and calcium salts.

Isoascorbic acid was evaluated by JECFA in 1961 and 1973. An ADI of 0-5 mg/kg bw was established by that Committee on the basis of a long-term study in rats. Since that time a considerable amount of additional studies have become available, which are concerned particularly with the biological behaviour of the substance. Therefore a reappraisal of the totality of the data had become necessary.

Although the apparent anti-scorbutic activity of single doses of isoascorbic acid is about 5% of that of ascorbic acid, large doses over prolonged periods will relieve the symptoms of scurvy. Isoascorbic acid is absorbed less efficiently and can compete with ascorbic acid for transport mechanisms. It reduces the ascorbic acid body pool and increases

ascorbic acid turnover, reduces its half-life and depresses the bioavailability of ascorbic acid by almost 50%. Isoascorbic acid is largely excreted in the urine but the fate in the body of 30-50% is unknown; nor are the metabolites known. Some human tissues appear to have stereospecific uptake. Unpublished data suggest failure of isoascorbic acid to be transported into granulocytes and inhibition of ascorbic acid uptake in man. The available short-term and long-term studies are inadequate as only one dose level was tested. Although no adverse effects were noted, there is no information on reproductive function or teratogenicity. The biological competition with ascorbic acid may be of significance for people with marginal ascorbic acid intake. The estimated intake may be 6-8% of the daily ascorbic acid requirement.

The Committee concluded that the available data are inadequate for full toxicological evaluation of the substance. Furthermore, the Committee was aware of the possibility that the observed competitive interference of isoascorbic acid with the absorption and distribution of ascorbic acid, and the resultant depletion of body reserves of ascorbic acid, could be of significance for people with border line intakes of ascorbic acid. The Committee was therefore of the opinion that the use of isoascorbic acid in food and drink is not acceptable, and no ADI was established.

### Tocopherol extracts; alpha-, beta-, gamma- and delta-tocopherol; alpha-tocopherol acetate

Vitamin E consists of a group of eight closely related compounds, namely four tocopherols and four tocotrienols. Particularly abundant in vegetable oils are alpha-, beta-, gamma- and delta-tocopherol. They all contain an hydroxy-bearing aromatic ring system and an isoprenoid side-chain, but differ in the number of methyl groups bound to the aromatic ring. There are three such methyl groups in alpha-tocopherol, two in beta- and gamma-tocopherol, and only one in delta-tocopherol.

Nutritional deficiency of Vitamin E in rodents leads to sterility and muscular weakness and atrophy. In humans evidence of tocopherol deficiency approaching the severity of that noted in animals has been observed in patients with long-standing fat malabsorption in association with clinical conditions such as neuropathy and myopathy. The specific molecular functions of the Vitamin E compounds is not known with certainty but there is good evidence that they are closely associated with lipids throughout the body and active in stabilizing highly unsaturated fatty acids in the cell against oxidation. A protective effect of tocopherols on the integrity of cell membranes is also established. In evaluating relative biological activities of the tocopherols including the anti-haemolytic and *in vivo* anti-oxidative activity, the number and position of the methyl groups in the benzene ring are important. The most active form is (d)-alpha-tocopherol. (d)-beta-tocopherol has about 25%-50% such activity; and (d)-gamma-tocopherol has about 10%-37% as much as (d)-alpha-tocopherol, depending on the assay used.

The recommended daily dietary intake of Vitamin E, expressed as (d)-alpha-tocopherol equivalents, is 10 mg/adult male and 8 mg/adult female. The recommended intake of Vitamin E increases during pregnancy and lactation by 1 and 3 mg/day, respectively. These intakes are likely to be met by the levels of tocopherols naturally occurring in many foods such as vegetable oils, cereals, nuts and leafy vegetables.

Clinical data are available indicating that adult humans can ingest for a few years daily doses of Vitamin E in the order of 100 mg or above without adverse effects. Hypervitaminosis has been reported in human beings only at oral dosage levels in excess of 400 mg/day. An increased mortality risk has been claimed to be associated with intakes of Vitamin E in excess of 1 g/person/day. On the whole, these data are not sufficient to assess long-term effects in human subjects of high intakes of Vitamin E.

In view of their antioxidant properties, tocopherols are also used as additives in food to prevent the destructive, non-enzymatic attack of molecular oxygen on the double bonds of the polyunsaturated fatty acids. The relative antioxidant efficiency of the different tocopherols in foods depends upon the nature of the substrate, the temperature and, possibly, the concentration. For example, gamma-tocopherol was more active than delta-tocopherol and much more than alpha-tocopherol in inhibiting oxidation of lard at 97°C, whereas gamma-tocopherol was the most effective, closely followed by the alpha-form, in protecting safflower oil at 63°C.

The tocopherols commercially available as food additives are mixtures of natural compounds (E306) or single synthetic (d,l) alpha-(E307), gamma-(E308) and delta-tocopherol (E309). The E306 obtained from vegetable oils is a mixture of (d) alpha-, beta-, gamma- and delta-tocopherol; the proportion of these four forms varies according to the source of the oil. Thus, for example, (d) alpha-tocopherol is predominant in sunflower and olive oil, whereas (d) gamma- and delta-tocopherols predominate in soybean oil. Other mixtures, called "mixed tocopherols" and "80-20 mixed tocopherols", are sold mainly for their Vitamin E activity, they contain not more than 5% or 20% of non-alpha-tocopherol respectively, the rest being (d)alpha-tocopherol. Under some circumstances, tocopherol esters (i.e. acetate and succinate) of (d) alpha- or (d,l) alpha-forms are also commercially available.


Metabolism and toxicity data are almost entirely based on studies of alpha-tocopherol and its acetate.

Ingested tocopherols are absorbed, translocated to tissues and metabolised (d) alpha-tocopherol is retained in the tissues longer than other forms of Vitamin E.

Tocopherols (i.e. (d) alpha-tocopherol, (d,l) alpha-tocopherol and (d,l) alpha-tocopherol acetate) are characterised by very low acute oral toxicity. Several animal species can tolerate doses of 200 mg/kg bw without apparent toxic signs.

Conditions described as hypervitaminosis E, including changes in oestrus cycle and degenerative lesions of liver and myocardium, have been reported in guinea pigs, hamsters and rats on subchronic administration, particularly by intra-muscular dosage in the range of 1 g of alpha-tocopherol/kg bw or higher.

Chronic toxicity studies with (d,l) alpha-tocopherol acetate suggested a limit hepatic response to Vitamin E overload as judged by liver enzymes and weight. They also indicated the possibility of interactions with other vitamins, e.g. Vitamins A and K in the diet, and the need for preventing vitamin imbalance at high intakes of Vitamin E. However, a



dose-related onset of haemorrhage, controlled by Vitamin K supplementation, also occurs with BHT. Both antioxidants appear to act by altering the availability of Vitamin K. Apart from the fact that BHT is not a vitamin, the reasons for considering that its effect is "toxic", while that of tocopherol may reflect "vitamin imbalance" are based on differences in dose response and the fact that there is some evidence that tocopherol can also interact with Vitamin A. However, it should be pointed out that studies on the effect of low doses of tocopherol on the prothrombin time, in the absence of Vitamin K supplementation, have not been carried out. Studies in human subjects suggest that large doses of tocopherol only decrease the levels of Vitamin K dependent clotting factors in the presence of pre-existing abnormalities, e.g. warfarin therapy. At a dose level in rats of about 500 mg/kg bw/d and after Vitamin K supplementation, only some borderline and equivocal effects, such as vacuolation of hepatic macrophages, have been observed. Some metabolic effects (e.g. alterations in the levels of ADP, ATP, phospholipids and cholesterol in the liver, and in the excretion of thiamine and phosphorus) have been reported (abstracts only were available to the Committee) following subchronic administration of tocopherols and tocopherol esters to rats at dose levels close to or lower than 500 mg/kg bw. However, as indicated by the results of the long-term studies, these metabolic changes do not result in toxic manifestations on prolonged treatment.

No adequate reproductive or teratogenicity studies in mammals are available for tocopherols. Some investigations which only focussed on certain specific effects (e.g. fetal survival and resorption, and some testicular functions) have been carried out with (d,l) alpha-tocopherol acetate or (d) gamma-tocopherol, in several species, including rats, hamsters, rabbits and mice. These studies (which were only available as abstracts) did not indicate any adverse effects apart from increased mortality of off-spring in rabbits and hamsters at high doses (1 600 and 750 mg/kg bw respectively).

Several investigations have fed or injected rats or mice with various doses of (d) alpha-tocopherol, (d,l) delta-tocopherol or (d,l) alpha-tocopherol acetate and have reported no increased incidence of tumours. Some in vitro and in vivo experiments indicate that tocopherols may have a beneficial effect, interfering sometimes with the formation of mutagens or with the expression of carcinogenic effects.

Although only scanty information is available on the toxicity of beta-, gamma- and delta-tocopherol, the Commission, in view of the very large amount of experimental and clinical data available on alpha-tocopherol, and the chemical and biological similarity of the four tocopherols, decided to consider the four tocopherols and alpha-tocopherol acetate as toxicologically equivalent. The intake of tocopherols from natural sources will normally far exceed that from processed foods containing tocopherol as an antioxidant.

The Committee concluded that the use of tocopherols as antioxidants in food was acceptable and that it was not appropriate to establish an ADI.



## Gallates - propyl-, octyl-, dodecyl-

These three antioxidants are the n-propyl-, octyl- and dodecyl-esters of 3,4,5-trihydroxybenzoic acid. The purity of the compound is not less than 99% for propyl gallate and not less than 98.5% for octyl- and dodecyl gallates. Gallates are used as antioxidants in fats and oils (alone or in combination with other antioxidants) to prevent rancidity and spoilage; the gallates have been shown to be more effective antioxidants than BHA and BHT. Other food additive uses of gallates include shortenings, baked goods, candy, dried-milk, chewing gum base and food packaging materials. Information on intake is only available for propylgallate and has been estimated to be from 0.03-0.2 mg/kg bw/d.

In 1976 the Scientific Committee for Food (2nd Series) established a group ADI for propyl-, octyl- and dodecyl gallate for 0-0.2 mg/kg bw. This ADI was the same as that allocated by the WHO/FAO Joint Expert Committee on Food Additives in 1976 and confirmed in 1980. It was based on a NEL observed in a reproduction study in rats of 1 000 mg of octyl gallate/kg feed, equivalent to 50 mg/kg bw, with the use of a 250-fold safety factor. Further data have since become available, including liver enzyme induction, mutagenicity, 2-generation reproduction, carcinogenicity (mouse and rat) and promotion/inhibition studies.

Metabolic data are scarce but it is clear that propyl gallate is absorbed well and hydrolysed to propyl alcohol and gallic acid. The latter is further metabolised. Octyl- and dodecyl gallates are however far less well absorbed and only a minor proportion is hydrolysed to the alcohol and gallic acid. The acute toxicity of octyl- and dodecyl gallate is less than that of propyl gallate, possibly explained by the difference in absorption/metabolism. Gallates are mainly excreted in the faeces.

Gallates may cause skin sensitisation and subsequent exacerbation of the resulting contact dermatitis occurs in some such sensitized individuals after ingestion of gallates.

Short-term toxicity studies in rats, mice, guinea pigs, dogs and pigs were available to the Committee. Also, at least six long-term toxicity/carcinogenicity studies in rats and mice have been carried out with propyl gallate. About half of these studies were old and/or inadequate. Nevertheless, there was no evidence of any increase in tumour formation. The NEL was 1 170 mg/kg feed in one study and 5 000 mg/kg feed in at least two other studies. With octyl- and dodecyl gallates only one long-term toxicity study was available. In this old study no toxicity, nor increase in tumour incidence was noted with 5 000 mg/kg feed. The Committee considered that 5 000 mg/kg feed, equivalent to 250 mg/kg bw could be considered the NEL. In short-term studies propyl gallate did not cause hyperplasia in the rat forestomach.

Propyl gallate was tested for inhibitory and potentiation effects on carcinogenesis. Propyl gallate showed clear inhibitory properties against the induction of tumours by DMBA and/or nitrosamines; and on the effect of hepatotoxic compounds.

Reproduction and teratogenicity studies were carried out with propyl- and octyl gallate. From these studies it was concluded that gallates are not teratogenic. On the contrary, gallates protected rabbits against the teratogenic potential of hydroxyurea. In the reproduction studies, 2 500 mg/kg feed produced a few minor effects but 1 000 mg/kg feed was without effect.

A range of mutagenicity studies (including dominant lethal), host mediated assay, in vivo cytogenetic, and Ames tests, with propyl gallate were negative. (No tests have been carried out for gene mutation in mammalian cells.) No data were available for octyl- and dodecyl gallate.

The Committee concluded that although a few data were available for octyl- and dodecyl gallates, the fact that these compounds appeared to be less toxic than propyl gallate made the use of a group ADI acceptable. The Committee confirmed the previously established NEL of 50 mg/kg bw but did not think that there was any need to continue to use a safety factor of 250. The usual factor of 100 was applied.

The Committee therefore established a group ADI of 0-0.5 mg/kg bw for propyl-, octyl- and dodecyl gallates.

#### Butylated hydroxyanisole (BHA)

BHA is predominantly (85% or more) 3-tert-butyl-4-hydroxyanisole (3-BHA) with 15% or less of 2-tert-butyl-4-hydroxyanisole (2-BHA).

The Committee had previously considered BHA in 1978 and 1983. At that time biochemical, short- and long-term toxicity/carcinogenicity data were available, together with results from mutagenicity, teratogenicity and reproduction studies. There was no multigeneration study. Some observations had also been made in man.

The SCF evaluated BHA in 1983 following consideration of results from a Japanese study in which BHA had produced forestomach tumours in the rat. The Committee endorsed the opinion of an EC working party on BHA (October 1982) and emphasized that information should be obtained on whether BHA could produce epithelial hyperplasia in the oesophagus and/or glandular stomach of species without a forestomach, or if its action was specific for the rodent forestomach.

Since that time more work has been carried out to resolve the above questions and to determine the mechanism for the action of BHA, and whether or not BHA is genotoxic.

The previously available long-term studies in rats were carried out rather a long time ago and it is possible that the study designs may not have taken the same account of forestomach lesions as was the case in the more recent Japanese studies. Also the highest dose used previously was 0.5% BHA in the diet. In Ito's study 2% BHA in the rat diet

produced tumours but 0.5% did not, although hyperplasia was present. In a similar study carried out by Tomii and Aoki a few forestomach tumours were found at 1% dietary level of BHA. Because of the steep dose response curve these authors questioned whether there may be a threshold for the tumorigenic effect of BHA.

Many short-term studies have been carried out in several species to determine whether BHA's action is specifically on the forestomach epithelium, and whether there is a threshold for hyperplasia. Depending on the duration of the experiment, BHA has been shown to produce hyperplasia and/or tumours specifically in the forestomach of rats, mice and hamsters. The hyperplasia is reversible but the time taken for recovery depends on duration and level of dosage with BHA. The NEL for hyperplasia in the rat forestomach is 0.125% BHA in the diet.

In animals without a forestomach - guinea pig, dog, pig, monkey - BHA produced no histological effects (including no hyperplasia) in the oesophagus or glandular stomach. In gavage studies in the monkey, the mitotic index in the 'target' squamous epithelium of the distal oesophagus was raised at high dose levels, but not at 250 mg/kg bw.

The Committee concluded therefore that the action of BHA in producing forestomach hyperplasia and tumours in rodents may not be relevant for man.

Other data examined by the Committee included promotion studies and results of mutagenicity tests. BHA has been shown to have both inhibitory and promotional effects on tumour yield from treatment with known carcinogens - the inhibitory effect being stronger. Nearly all the available mutagenicity data were negative and BHA has not been demonstrated to be a genotoxic compound. This reinforced the Committee's view that the effects on the rat forestomach were not significant for assessing risks to human health.

The Committee had previously noted the lack of a multigeneration study. However, in a number of (1 generation) reproduction studies with rats, mice and monkeys, at dose levels of 50 mg/kg bw or higher no effects were observed except on the behaviour of mice. Teratogenicity studies were all negative. The Committee therefore agreed that a temporary ADI for BHA was now acceptable.

The Committee concluded that the production of rodent forestomach tumours by BHA was not a manifestation of genotoxicity; and that in addition to being an effect with a threshold, the preceding hyperplasia may not be of relevance for man. Further reassurance was to be found in the results of studies in species without a forestomach. In setting an ADI the Committee took into account that :

- (a) the NEL in a 90-day study for production of hyperplasia in the rat forestomach (62.5 mg/kg bw). Given the evidence of lack of effect in more relevant species, the Committee considered that a safety factor of 100 was adequate;

and

- (b) the NEL of 250 mg/kg bw previously determined in a long-term chronic toxicity feeding study - on the basis of which JECFA had established a temporary ADI of 0-0.5 mg/kg bw (using a safety factor of 500).

The Committee established a temporary ADI of 0-0.5 mg/kg bw.

The Committee noted that the actual (estimated) daily intake of BHA is far less than that allowed by the temporary ADI. The Committee wishes regularly to review the status of BHA, and information from ongoing studies and on actual intakes.

### Butylated Hydroxytoluene (BHT)

The Committee has reviewed all available studies on BHT, including metabolic data from several species including man, mutagenicity studies, carcinogenicity studies in rats and mice, and special studies on the thyroid, blood and postnatal development and behaviour.

A recent two-generation feeding study in the rat showed an increased incidence of hepatocellular adenomas and carcinomas at the two higher dose levels (100 and 250 mg/kg bw). All the tumours were first noted after two years, the majority at termination between 141 and 144 weeks; and the survival of control animals was markedly poorer than in those fed BHT. Previous feeding studies in rats have not shown such carcinogenic effects. The Committee's view that the recent study suggests a threshold for carcinogenesis (related to liver enzyme induction) was reinforced by the results obtained from mutagenicity testing, with an overall lack of evidence of genotoxic effect in in vivo systems. Like other antioxidants BHT can exhibit promoting or inhibiting effects on carcinogenesis. BHT does not cause hyperplasia in the rat forestomach. Effects on mitotic rate are diverse.

Since the NEL demonstrated for carcinogenesis was higher than that obtained for other toxicological effects, the ADI was determined from the latter.

The information available from a 90-day feeding study in the rat indicated there was a dose-related increase in relative thyroid weight of 40% and 67% in the 500 and 5 000 ppm BHT groups respectively; iodine uptake and the height of follicular epithelial cells were increased at 5 000 ppm (not measured at 500 ppm). However, blood levels of tri-iodothyronine and thyroxine at both dietary levels were unchanged, and the increase in the half-life of thyroxine seen early in the study was only transient. In the in utero exposure rat carcinogenicity study, a 5% reduction in offspring body weight at weaning was seen in those reared by dams fed 25 mg/kg bw, equivalent to approximately 500 ppm BHT in the diet. Since these effects on the thyroid and on offspring body weight were found at the lowest levels tested in these particular studies, NEL have not been clearly established. In view of these data, and the nature of the effects observed, it is reasonable to assume the likely NEL for thyroid and offspring body weight changes will be about 5-fold lower than the lowest-observed-effect level, i.e. about 100 ppm in the diet.

A series of haematological studies has shown that some, but not all species tested show haemorrhaging and/or a reduction in the prothrombin index after dosing with BHT. The mechanisms by which BHT brings about these effects appear to be several but the major effect is a reduction in activity of certain clotting factors, principally those which are Vitamin K-dependent. The most susceptible species for haemorrhagic effects appears to be the rat, and for this species the NEL for transient reduction (1 week's duration) of the prothrombin index was 85 ppm in the diet, and for persistent reduction (4 weeks' duration), 2 500 ppm in the diet.

Taking all these effects into account, the Committee considered that the likely NEL for BHT is approximately 100 ppm in the diet, equivalent to an intake of about 5 mg/kg bw/d. In view of the nature of the effects, a safety margin of 100-fold is appropriate to establish an ADI of 0-0.05 mg/kg bw based on thyroid, reproduction and haematological effects in the rat.

### Tertiary-butylhydroquinone (TBHQ)

The Committee previously expressed its opinion on TBHQ in December 1981 when it drew attention to the lack of adequate data on which to assess the genotoxic and carcinogenic potential of this antioxidant. The Committee, therefore, did not establish an ADI at that time.

Since then, further in vitro and in vivo mutagenicity data have become available which do not exclude the possible genotoxicity of TBHQ.

The Committee therefore restated the need for an adequate carcinogenicity study and also requested an in vivo mutagenicity study of germ cell effects.

The Committee did not establish an ADI for TBHQ, and the substance is not acceptable for use as an antioxidant to food.



## REFERENCES

### Ascorbic acid

Sebrell, W.H., Jr. and Harris, R.S., (Eds.), (1967), *The Vitamins : chemistry, physiology, pathology, methods*. Vol. 1., 2nd ed., Acad. Press Inc., N.Y.

Passmore, R., (1977), How vitamin C deficiency injures the body. *Nutr. Today*, 12 (6-11), 27-31.

Starsen, F.L.H., Cardinale, G.J. and Udenfried, S., (1973), Activation of prolyl hydroxylase in L-929 fibroblasts by ascorbic acid. *Proc. Natl. Acad. Sci., USA*, 70, 1090-1093.

Ginter, E., (1973), Cholesterol : vitamin C controls its transformation to bile acids. *Science*, 179, 702-704.

Krumdieck, C. and Butterworth, C.E., Jr., (1974), Ascorbate-cholesterol-lecithin interactions : factors of potential importance in the pathogenesis of atherosclerosis. *Am. J. Clin. Nutr.*, 27, 866-876.

Baker, E.M., III, Hammer, D.C., March, S.C., Tolbert, B.M. and Canham, J.E., (1971), Ascorbate sulfate : a urinary metabolite of ascorbic acid in man. *Science*, 173, 826-827.

La Du, B.N. and Zannoni, V.G., (1961), The role of ascorbic acid in tryosine metabolism. *Ann. N.Y. Acad. Sci.*, 92, 175-191.

King, C.G. and Burns, J.J., (Eds.), (1975), *Second conference on vitamin C*. *Ann. N.Y. Acad. Sci.*, 258, 552 pp.

FASEB, (1979), Evaluation of the health aspects of ascorbic acid, sodium ascorbate, calcium ascorbate, erythorbic acid, sodium erythorbate and ascorbyl palmitate as Food Ingredients. SCOGS 59.

WHO, (1974), *Food Additive Series*, No. 5, 143-5.

FDRL (Food and Drug Research Laboratories, Inc.), (1975), *Teratologic evaluation of FDA 71-65 (ascorbic acid) in mice and rats*. Final Report, Waverly, N.Y.

Naber, E.C., (?), Investigations on the toxic and teratogenic effects of GRAS substances on the developing chick embryo, FDA Contract 72-343, Ohio State University.

Verrett, M.J., (1977), Investigations of the toxic and teratogenic effects of GRAS substances to the developing chicken embryo : calcium ascorbate. FDA, Washington.

Litton Bionetics, Inc., (1975), Mutagenic evaluation of the compound FDA 71-65, ascorbic acid, Kensington, Md.

Litton Bionetics, Inc., (1976a), Mutagenicity evaluation of sodium ascorbate. FDA 75-64, Final Report, Kensington, Md.

Litton Bionetics, Inc., (1976b), Mutagenicity evaluation of calcium ascorbate, FDA 75-63, Final Report, Kensington, Md.

Frohberg, H., Gleich, J. and Kieser, H., (1973), Reproduktions-Toxikologische Studien mit Ascorbinsäure an Mäusen und Ratten. *Arzneim. Forsch.*, 23, 1081-1082.

Rivers, J.M., (1974), Relationships of ascorbic acid to pregnancy and oral contraceptive steroids. *Trans. N.Y. Acad. Sci.*, 36, 817-818 (Abstract).

Lowry, O.H., Bessey, O.A. and Burch, H.B., (1952), Effects of prolonged high dosage with ascorbic acid. *Proc. Soc. Exp. Biol. Med.*, 80, 361-362.

Cook, J.D. and Monsen, E.R., (1977), Vitamin C, the common cold, and iron absorption. *Am. J. Clin. Nutr.*, 30, 235-241.

Landen, M.P. and Chrystowski, G.A., (1954), Urinary oxalate excretion by man following ascorbic acid ingestion. *Proc. Soc. Exp. Biol. Med.*, 85, 190-192.

Hagler, L. and Herman, R.H., (1973), Oxalate metabolism. I. *Am. J. Clin. Nutr.*, 26, 758-765.

Abbasy, M.A., (1937), *Biochem. J.*, 31, 339.

Abt, A.F. and Farmer, C.J., (1938), *J. Amer. med. Ass.*, 111, 1555.



Curtin, C.O'H. and King, C.G., (1955), *J. biol. Chem.*, 216, 539.

Evans, W., (1938), *Lancet*, 1, 308.

Surber, W. and Cerioli, A., (1971), a two-year toxicity study with L-ascorbic acid on the rats. Unpublished report of the Battelle Laboratories submitted by Hoffman-La Roche AG.

Widenbauer, F., (1936), *Klin. Wschr.*, 33, 1157.

Food Chemical News (FCN), dated 18/7/83, pg 29.

Baker, E.M., Sauberlich, H.E., Wolfskill, S.J., Wallace, W.T. and Dean, E.E., (1962), <sup>14</sup>C Tracer studies of vitamin C utilization in men: metabolism of D-glucuronolactone-6-C<sup>14</sup>, D-glucuronic-6-C<sup>14</sup> acid and L-ascorbic-1-C<sup>14</sup> acid. *Proc. Soc. Exp. Biol. Med.*, 109, 737-741.

Anderson, T.W., Reid, D.B.W. and Beaton, G.H., (1972), Vitamin C and the common cold: a double blind trial. *Can. Med. Assoc. J.*, 107, 503-508.

Briggs, M.H., Garcia-Webb, P. and Davies, P., (1973), Urinary oxalate and vitamin C supplements. *Lancet*, 2, 201.

Herbert V. and Jacob, E., (1974), Destruction of vitamin B<sub>12</sub> by ascorbic acid, *J. Amer. Med. Assoc.*, 230, 241-242.

Newmark, H.L., Scheiner, J., Marcus, M. and Prabhudesai, M., (1976), Stability of vitamin B<sub>12</sub> in the presence of ascorbic acid. *Am. J. Clin. Nutr.*, 29, 645-649.

Hellman, L. and Burns, J.J., (1958), Metabolism of L-ascorbic acid-1-C<sup>14</sup> in man. *J. Biol. Chem.*, 230, 923-930.

Kallner, A., Hartmann, D. and Hornig, D., (1979), Steady-state turnover and body pool of ascorbic acid in man. *Am. J. Clin. Nutr.*, 32, 530-539.

Siliprandi, L., Vanni, P., Kessler, M. and Semenza, G., (1979), Na<sup>+</sup>-dependent, electroneutral L-ascorbate transport across brush border membrane vesicles from guinea pig small intestine. *Biochem. Biophys. Acta* 552, 129-142.

Baker, E.M., Halver, J.E. Johnson, D.O., Joyce, B.E., Knight, M.K. and Tolbert, B.M., (1975), Metabolism of ascorbic acid and ascorbic-2-sulfate in man and the subhuman primate. *Ann. N.Y. Acad. Sci.* 258, 72-80.

Tolbert, B.M., Chen, A.W., Bell, E.M. and Baker, E.M., (1967), Metabolism of L-ascorbic-4-<sup>3</sup>H acid in man. *Am. J. Clin. Nutr.*, 20, 250-252.

Atkins, G.L., Dean, B.M., Griffin, W.J. and Watts, R.W.E., (1964), Quantitative aspects of ascorbic acid metabolism in man. *J. Biol. Chem.*, 239, 2975-2980.

Demole, V., (1934), On the physiological action of ascorbic acid and some related compounds. *Biochem. J.*, 28, 770-773.

Körner, W.F. and Weber, F., (1972), Zur Toleranz hoher Ascorbinsäuredosen. *Int. Z. Vitam. Ern. Forsch.*, 42, 528-544.

Joint FAO/WHO Expert Committee on Food Additives, (1962), Page 20 in Evaluation of the toxicity of a number of antimicrobials and antioxidants. 6th Report. Food and Agriculture Organization of the United Nations, Rome, and the World Health Organization, Geneva.

Cagli, V., Cantore, G.P., Pecori Giraldi, J. and Vimo, M., (1965), Azione diuretica dell'ascorbato di sodio : osservazioni sugli animali e sull'uomo. *Policlinico Sez. Prat.*, 72, 836-842.

Kieckebusch, W., Griem, W. and Lang, K., (1963), Untersuchungen über die chronische Toxizität der Ascorbinsäure bei der Ratte. *Z. Ernähr.*, 4, 5-14.

De Albuquerque, A. and Henriques, M.A., (1970), Ensaíos sobre a toxicidade do ácido ascorbico. *Rev. Port. Farm.*, 20 (2), 41-46.

STEEL, M.L., (1969), Growth and reproduction of guinea pigs fed three levels of ascorbic acid. *Diss. Abstr.*, 29, 4727B.

Kienholz, E.W., Bell, D.D., Wookey, K.M. and Wookey, L.E., (1971), Effect of high levels of ascorbic acid in diets for chicks. *Fed. Proc. Fed. Am. Soc. Exp. Biol.*, 30, 521 (Abstract).

Hines, J.D., (1975), Ascorbic acid and vitamin B<sub>12</sub> deficiency, J. Am. Med. Ass., 234, 24.

Lewis, T.L., Karlowski, T.R., Kapikian, A.Z., Lynch, J.M., Shaffer, G.W. and George, D.A., (1975), A controlled clinical trial of ascorbic acid for the common cold. Ann. N.Y. Acad. Sci. 258, 505-512.

Mengel, C.E. and Greene, H.L. Jr., (1976), Ascorbic acid effects on erythrocytes. Ann. Intern. Med., 84, 490.

Miller, J.Z., Nance, W.E., Norton, J.A., Wolen, R.S., Griffith, R.S. and Rose, R.J., (1977), Therapeutic effect of vitamin C : a co-twin control study. J. Am. Med. Ass., 237, 248-251.

Rhead, W.J. and Schrauzer, G.N., (1971), Risks of long-term ascorbic acid overdosage. Nutr. Rev., 29, 262-263.

Rosenthal, G., (1971), Interaction of ascorbic acid and warfarin. J. Amer. Med. Ass., 215, 1671.

Shilotri, P.G. and Bath, K.S., (1977), Effect of mega doses of vitamin C on bactericidal activity of leukocytes. Am. J. Clin. Nutr., 30, 1077-1081.

Sorensen, D.I., Devine, M.M. and Rivers, J.M., (1974), Catabolism and tissue levels of ascorbic acid following long-term massive doses in the guinea pig. J. Nutr. 104, 1041-1048.

Newberne, P.M. and Suphakarn, V., (1983), Nutrition and Cancer : A review with emphasis on the role of vitamins C and E and Selenium. Nutr. Canc., 5(2), 107-119.

Fukushima, S., Kurata, Y., Shibata, M., IKAWA, E. and Ito, N. (1984). Promotion by ascorbic acid, sodium erythorbate and ethoxyquine of neoplastic lesions in rats initiated with BNN. Cancer Lett., 23, 29-37.

WHO, (1981), Food Additive Series No. 16, 52-59.

Norkus, E.P., Kuenzig, W. and Conney, A.H., (1983), Studies on the mutagenic activity of ascorbic acid in vitro and in vivo. Mutation Res., 117, 183-191.

Shamberger, R.J., (1984), The genetic toxicology of ascorbic acid. Mutation Res., 133, 135-159.

Sutton et al., (1983), Br.J.Nutr., 49, 27.

Zannoni et al., (1972), Biochem. Pharmac., 21, 1377.

Holloway and Rivers, (1981), J. Nutr. 111, 412.

### Iso-ascorbic acid

Fabianek, J. and Herp, A., (1967), Antiscorbutic activity of D-araboascorbic acid, Proc. Soc. exp. Biol. Med. 125, 462.

FASEB, (1979), Evaluation of the Aspects of ascorbic acid, sodium ascorbate, calcium ascorbate, erythorbic acid, sodium erythorbate and ascorbyl palmitate as food ingredients, SCOGS-59.

Fitzhugh, C.G. and Nelson, A.A., (1946), Proc. Soc. Exp. Biol., 61, 193.

Gould, D.S., (1979), Food Chem. News, 6th Aug. 1979, pg. 5.

Hofman, I., van Dijk, R., de Vries, J. and van de Haar, G., (1981), De Vloeistofchromatografische Bepaling van L-(+)-ascorbinezuur en D-isoascorbinezuur in Levensmiddelen. De Ware(n)-Chemicus, 11, 84-90.

Hornig, D., (1977), Interaction of erythorbic acid with ascorbic acid. Catabolism. Acta. Vitamin, enzymol (Milano), 31, 9-14.

Hornig, D., Weber, F. and Wiss, O., (1973), Influence of erythorbic acid on the vitamin C status in guinea pigs. Experientia, 30, 173-174.

Hornig, D. and Weiser, H., (1976), Interaction of erythorbic acid with ascorbic acid catabolism. Internat. J. Vit. Nat. Res., 46, 40-47.

Hughes, R.E. and Hurley, R.J., (1969), The uptake of D-araboascorbic acid (D-isoascorbic acid) by guinea pig tissues. Brit.J.Nutr., 23, 211.

Hughes, R.E., Hurley, R.J. and Jones, P.R., (1971), Vitamin C activity of D-araboascorbic acid. Nutr. Rep. Intern., 4 (4), 177-183.

Hughes, R.E. and Jones, P.R., (1970), D-araboascorbic acid and guinea pig survey. *Nutr. Rep. Intern.*, 1(5), 275-279.

Kadin, H. and Osadca, M. (1959), *J. Agric. Food Chem.*, 7, 358.

Lehman, A.J., O.G. Fitzhugh, A.A. NELSON, and G. Woodard., 1951, The pharmacological evaluation of antioxidants. *Adv. Food Res.* 3 : 197-208.

Linner, E., and Nordström., K., (1969), Transfer of D-isoascorbic acid and L-ascorbic acid into guinea pig eyes. *Docum. Ophthalm.* 26, 164-170.

Pelletier, O., (1969), Turnover rates of D-isoascorbic acid and L-ascorbic acid in guinea pig organs. *Canad. J. Phys. Pharm.*, 47, 993-997.

Pelletier, O. and Godin, C., (1969), Vitamin C activity of ascorbic acid for the guinea pig. *Can. J. Physiol. Pharmacol.*, 47, 985-991.

Rivers, J.M., Huary, E.D. and Dodds, M.L., (1963), Human Metabolism of L-Ascorbic Acid and Erythorbic Acid. *J. Nutr.* 61, 163-168.

Siliprandi, L., Vanni, P., Kessler, M. and Semenza, G., (1979), Na<sup>+</sup>-dependent, electroneutral L-ascorbate transport across brush border membrane vesicles from guinea pig small intestine. *Bioch. et Bioph. Acta*, 552, 129-142.

Spector, R. and Lorenzo, A.V., (1974), Specificity of ascorbic acid transport system of the central nervous system. *Amer. J. Physiol.*, 226/6, 1468-1473.

Spencer, R.P., Purdy, S., Hoeldtke, R., Bow, T.M. and Markulis, M.A., (1963), *Gastroenterology*, 44, 768-773.

Toggenburger, G., Häusemann, M., Mütsch, B., Genoni, G., Kessler, M. Weber, F., Hornig, D., O'Neill, B. and Semenza, G., (1981), Na<sup>+</sup>-dependent, potential sensitive, L-ascorbate transport across Brush Border Membrane Vesicles from Kidney Cortex. *Biochem. Biophys. Acta*, 646, 433-443.

Toggenburger, G., Landolt, M. and Semenza, G., (1979), Na<sup>+</sup>-dependent, electroneutral L-ascorbate transport across brush border membrane vesicles from human small intestine. *FEBS Letters*, 108 (2), 473-476.

Tsao, C.S. and Salimi, S.L., (1983), Influence of erythorbic acid on ascorbic acid retention and elimination in the mouse. Intern. J. Vit. Nutr. Res. 53, 258-264.

Wang, M.M., Fisher, K.H. and Dodds, M.L., (1962), Comparative metabolic response to erythorbic acid and ascorbic acid by the human. J. Nutr. 77, 443-447.

WHO, (1974), Food Additive Series No. 5, 193.

Orahovats, P.D., (1957), Toxicity studies with d-isoascorbic acid. FPC No. 0078. Merck Institute of Therapeutic Research, Rahway, N.J. 2pp.

Food and Drug Research Laboratories (FDRL), (1974), Teratologic evaluation of FDA 71-68 (sodium erythorbate) in mice and rats. Final Report, Waverly, N.Y.

Naber, E.C. ( ), Investigations on the toxic and teratogenic effects of GRAS substances on the developing chick embryo (sodium erythorbate). FDA contract 72-343. Ohio State University, Ohio.

Hwang, U.K., (1974), Investigations of the toxic and teratogenic effects of GRAS substances to the developing chicken embryo, erythorbic acid. St. Louis University School of Medicine, St. Louis, Mo.

Newell, G.N., Jorgenson, T.A., and Simmon, V.F., (1974), Study of mutagenic effects of sodium erythorbate (FDA 71-68). Compound report No. 4. Stanford Research Institute, Menlo Park, California.

### Tocopherols

Mason, K.E., (1980), The first two decades of vitamin E history in "Vitamin E, a comprehensive treatise", Lawrence J. Machlin ed. M. Dekker, Inc. publ. pag. 1-6.

Kasperek, S., (1980), Chemistry of tocopherols and tocotrienols in "Vitamin E, a comprehensive treatise", Lawrence J. Machlin ed. M. Dakker, Inc. publ. pag. 6-65.

Vitamin E Questions & Answers, (1979), Henkel Corporation, Minneapolis, Minnesota.

Federal Register, (1978), Vol. 43, N° 209, Friday, October 27, pag. 50193-7.

From appendix A, in "Vitamin E a comprehensive treatise", (1980), Lawrence J. Machlin ed. M. Dekker, Inc. publ. pag. 133-153 .

Specifications for identity and purity of some food additives, 21th report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Tech. Rep. Series N° 617, Roma, (1977).

Idrajit D. Desai, (1980), Assay methods, in "Vitamin E, a comprehensive treatise", Lawrence J. Machlin ed. M. Dakker Inc. publ. pag. 67-98.

Slover, H.T., Thompson, R.H. Jr. and Merola, G.V., (1993), Determination of tocopherol and sterols by capillary gas chromatography, JAOCS, Vol. 60, pag. 1524-8.

Faria, J.A.F., (1982), A gas chromatographic reactor to measure the effectiveness of antioxidants for polyunsaturated lipids, JAOCS, Vol.59, pag. 533-5.

Thompson, W.J., Hatina, G., (1979), Determination of tocopherols and tocotrienols in foods and tissues by high performance liquid chromatography. J. Liquid. Chromatography, Vol. 2, 327-344.

Micali, G., Curro, P., (1984), Determinazione dei tocoferoli negli olii vegetali mediante HPLC, Riv. Ital. Sost. Grasse, Vol. LXI, pag. 95-98.

Juliet, H.T. (1975), Fette Sciefen Anstrichim. 77, 101 cited by Baunenfield : Food Sources of tocopherols (5).

Gallo-Torrese, E.H., (1980), Absorption, in "Vitamin E, a comprehensive treatise", Lawrence J. Machlin ed. M. Dakker, Inc. Publ., pag. 170-192.

Pearson and Bauson, cited in Bauernfied : Food Sources of tocopherols (4).

Schmandke et al. cited in Bauernfied : Food Sources of tocopherols (4).

Bieri, J.G., (1972), Aspects of vitamin E metabolism relating to the dietary requirement, Ann. New York Acc. of Sci 203, pag. 182-191.

Simon et al. cited in : Bauernfied : Food Sources of tocopherols (4).

Tappel, A1. L., (1980), Vitamin E and selenium protection from in vivo lipid peroxidation, Ann. New York Acc. of Sci. Vol. 355, pag. 18-29.

McCay, P.B. and King, M.M., (1980), in "Vitamin E : its role as a biologic free radical scavenger and its relationship to the microsomal mixed-function oxidase system, in Vitamin E a comprehensive treatise, Lawrence J. Machlin ed. M. Dakker, Inc. publ., pag. 289-312.

Zonta, F., Stancher, B., (1983), High performance liquid chromatography of tocopherols in oils and fats, Riv. Ital. Sost. Grasse, Vol. LX, pag. 195-199.

Bazin, B., Cillard, J., Koskas, K.P. and Cillard, P., (1984), Arachidonic acid autoxidation in an aqueous media effect of alpha-tocopherol, cysteine and nucleic acids, JAACS Vol. 61, pag. 1212-1215.

Hildebrand, D.H., Terao, J. and Kito, M., (1984), Phospholipids plus tocopherols increase soya bean oil stability, JAACS vol. 61, pag. 552-555.

Ishikawa, Y., Sugiyama, K., and Nakabayashi, K., (1984), Stabilization of tocopherol by three components synergism involving tocopherol, phospholipid and amino compound, JAACS, Vol. 61, pag. 950-954.

Witting, L.A., (1969), The oxidation of alpha-tocopherol during the autoxidation of ethyl oleate, linoleate, linolenate, and arachidonate, Arch. Biochem. Biophys., 129, pag. 142-151.

Dillard, J.C., Gavino, C.V. and Tappel, L.A., (1983), Relative antioxidant effectiveness of alpha-tocopherol and beta-tocopherol in Iron-loaded rats. J. Nutr., 113, 2266-2273.

Kitabchi, A.E., and Wimalasena, J., (1982), Specific binding sites for d-alpha-tocopherol on human erythrocytes, Bioch. Biophys. Acta, 684 pag. 200-206.

Stampfer, M.J., Willet, W., Castelli, W.P., Taylor, O., Fine, J. and Hennekens, C.H., (1983), Effect of vitamin E on lipids, Am. J. Clin. Path., Vol. 79, pag. 714-716.

Serfontein, W.J., Ubbink, J.B. and Villiers, L.S., (1983), Further evidence on the effect of vitamin E on the cholesterol distribution in lipoproteins with special reference to HDL subfractions, Am. J. Clin. Path. Vol., 79, pag. 604-606.

Corcos-Benedetti, P., D'Aquino, M., Di Felice, M., Tagliamonte, B., Tomassi, G., Effects of the thermoxidative fraction of soya bean oil on lipid peroxidation and vitamin E and A status of growing rats. Proc. VI. Intern. Congress of Food Sci. and Technol. Dublin, Spet., 18-23, 1983, Vol. 3, pag. 75.



Murphy, T.P., Wright, K.E. and Pudelkiewicz, W.J., (1980), An apparent rachitogenic effect of excessive vitamin E intakes in the chick. *Poultry Science*, 60, pag. 1873-1878.

McCuaig, L.W. and Motzok, I., (1970), Excessive dietary Vitamin E : its alleviation of hypervitaminosis A and lack of toxicity. *Poultry Science*, 49, pag. 1050-1052.

Tenkins, Y.M. and Mitchell, G.V., (1975), Influence of excess vitamin E on vitamin A toxicity in rats. *J. of Nutr.*, 105, pag. 1600-1606.

March, B.E., Coates, V. and Brely, J., (1969), Reticulocytosis in response to dietary antioxidants. *Science*, 164, pag. 1398-1400.

Krasavage, W.J. and Terhaar, C.J., (1977), d-alpha-tocopheryl poly (ethylen glycol) 1000 succinate. Acute toxicity, subchronic feeding, reproduction and teratologic studies in the rat. *J. Agr. Food. Chem.*, 25, 273-8.

Dymsza, H.A. and Park, J., (1975), Excess dietary vitamin E in rats. *Fed. Proc. Am. Soc. Exp. Biol.*, 34, 912.

Yang, N.Y. and Desai, I.D., (1977), Effect of high levels of dietary vitamin E on hematological indices and biochemical parameters in rats. *J. of Nutr.*, 107, 1410-1417.

Weldon, G.H. and Bhatt, A., (1983), dl-alpha-tocopheryl acetate (vitamin E), a long-term toxicity and carcinogenicity study in rats.

*Intern. J. Vit. Nutr. Res.* 53, pag. 287-296.

Welch, cited in (4).

Farrell, P.M. and Bieri, J.G., (1975), Megavitamin E supplementation in man. *Am. J. Clin. Nutr.* 28, pag. 1381-1386.

Wartanowicz, M., Panczenko-Kresowka, B., Ziemiński, S., Kowalska, M. and Okolska, G., (1984), The effect of alpha-tocopherol and ascorbic acid on the serum lipid peroxide level in elderly people. *Ann. Nutr. Metab.*, 28, pag. 186-191.

Megavitamin E supplementation and vitamin K-dependent carboxylation, (1983), *Nutr. Reviews*, vol. 41, 268-270.

Dion P.W., Bright-See S., Smith, C.C. and Bruce, W.R., (1982), The effect of dietary ascorbic acid and alpha-tocopherol on fecal mutagenicity. *Mutation Res.*, 102, pag. 27-37.

Shamberger, R.J., Baughan, F.F., Kalchert, S.L., Willis, C.E., Hoffman, G.C., (1973), Carcinogen induced chromosomal heakage decreased by antioxidants.

*Proc. Nat. Aca. Sci.* 70, 1461.

Kodytkova cited by (41).

Kodytkova, J., Madar, J. and Sram, R.J., (1980), Chromosomal aberrations in mouse bone marrow cells and antibody production changes induced by long-term exposure to cyclophosphamide and alpha-tocopherol.

*Folia Biol. (Praha)*, Vol., 26, pag. 94-102.

IP, C., (1982), Dietary vitamin E intake and mammary carcinogenesis in rats. *Carcinogenesis*, Vol. 3, pag. 1453-1456.

Soliman, cited by (4).

### Gallates

Abdo, K.M., Huff, J.E., Haseman, J.K., Dieter, M.P., Boorman, G.A., Hildebrandt, P., Prejean, J.D. and Farnell, D.R., (1983), Carcinogenesis Bio-assay of Propylgallate in F344 Rats and B6C3F1 Mice. *Journal of the Am. Coll. of Toxicol.*, vol., 2, 6, 425-433.

Allen, C.S., and De Eds, F.D., (1951), The chronic toxicity of laurylgallate. *J. Amer. Oil. Chem. Soc.*, 28, 304.

Archer, D.L., Smith, B.G., Ulrich, J.T. and Johnson, H.M., (1979), Immune interferon induction by T-cell mitogens involves different T-cell subpopulations. *Cellular Immunology*, 48, 420-426.

Archer, D.L. and Wess, J.A., (1979), Chemical dissection of the primary and secondary in vitro antibody responses with butylated hydroxyanisole and gallic acid. *Drug and Chem. Toxicol.*, 2, 155-166.

Astill, B.D. and Mulligan, L.T., (1977), Phenolic antioxidants and the inhibition of hepatotoxicity from n-dimethylnitrosamine formed in situ in the rat stomach. *Food Cosmet. Toxicol.*, 15, 167-171.

Blackmore, R.H. and Voelker, R.W., (1969), 13-week dietary administration, Rats. Octylgallate. Unpublished report from Hazleton Labs., Project No. 458-115.

Booth, A., Masri, M., Robbins, D., Emerson, O., Jones, F., and De Eds, F., (1959), The metabolic fate of gallic acid and related compounds. *J. Biol. Chem.*, 234, 3016.

Brun, R., (1970), Eczéma de contact à un anti-oxydant de la margarine (gallate) et changement de métier. *Dermatologica*, 140, 390.

Buckman, N.D., (1962), The effect of propylgallate antioxidant upon the nutritional value of fats. *Vop. Pitan*, 21, 68-72.

Burckhardt, W. and Fierz, U., (1964), Anti-oxydantien in der Margarine als Ursache von Gewerbeekzemen. *Dermatologica*, 129, 431-432.

Carpenter, M., (1981), Antioxidant effect on the prostaglandin endoperoxide synthetase product profile. *Fed. Proc.*, 40(2), 189-194.

Cheng, D.W., Chang, L.F. and Baimson, T.A., (1957), Gross observations on developing abnormal embryos induced by maternal vitamin E deficiency. *Anat. Rec.*, 129, 167-173.

Collins, A.J. and Sharrat, M., (1970), The BHT contents of human adipose tissue. *Food Cosmet. Toxicol.*, 8, 409-414.

Dacre, J.C., (1960), Metabolic pathways of the phenolic antioxidants. *J. New Zeal. Inst. Chem.*, 24, 161.

Dacre, J.C., (1974), Long-term toxicity study on n-propylgallate in mice. *Food Cosmet. Toxicol.*, 12, 125-129.

Depner, M., Kahl, G.F. and Kahl, R., (1982), Influence of gallic esters on drug-metabolizing enzymes of rat liver. *Food Chem. Toxic.*, 20, 507-511.

DeSesso, J.M., (1981), Amelioration of teratogenesis I. Modification of hydroxyurea-induced teratogenesis by the antioxidant propylgallate. *Teratology*, 24, 19-35.

Documents of pathology working group, 4-country Joint meeting. Meeting between representatives of US, UK, Canada and Japan. Nov. 16, (1982).

Esch, G.J. van, (1955), The toxicity of the antioxidants propyl-, octyl- and dodecylgallate : Voeding, 16, 683-686.

Food and Drug Laboratories, (1973), Teratologie evaluation of FDA, 71-39, (propylgallate). NTIS, Report, PB-223-816.

Gammal, E.B., Carroll, K.K. and Plunkett, E.R., (1967), Effects of dietary fat on mammary carcinogenesis by 7.12-dimethylbenz(a)anthracene in rats. Cancer Res., 27, 1737-1742.

General report of meeting of chemistry group on antioxidants. Nov., 1-3, (1982). Meeting between representatives of US, UK, Canada and Japan.

Gorbacheva, L., Kukushkina, G. and Petrov, O., (1966), Retardation of tumor growth and RNA biosynthesis by administration of phenolic compounds to tumor-bearing animals. Fenal'nye Soedin Ikh. Finkts, Mater Veses Simp., 345-348.

Hazleton Lab. Inc., (1969a), 13-week dietary feedings, Rats. Octylgallate. Unpublished report from Hazleton Labs., Project, No. 458-117.

Hazleton Lab. Inc., (1970), Modified two-generation reproduction study, Rats. Octylgallate. Unpublished report from Hazleton Labs., Project, No. 458-116.

Hazleton Lab. Inc., (1969b), 13-week dietary feedings, Dogs. Octylgallate. Unpublished report from Hazleton Labs., Project No. 458-115.

Industrial Bio-test Labs., (1970a), Ninety-day subacute oral toxicity study with Cold-Pro, GA-8 in Beagle dogs. Unpublished report from Industrial Bio-Test Labs., IBT, No. C8472.

Industrial Bio-test Labs., (1970b), Three generation reproduction study with Cold-Pro, Ga-8 in albino rats. Unpublished report from Industrial Bio-Test Labs., IBT No. P84.

Industrial Bio-test Labs., (1971a), Human repeated insult patch test with *n*-octylgallate. Unpublished report from Industrial Bio-Test Labs., IBT No. F9309.

Industrial Bio-test Labs., (1971b), Oral mucosa irritation/sensitization test with treated beer. Unpublished report from Industrial Bio-Test Labs., IBT No. F9310.

Industrial Bio-test Labs., (1971c), Oral mucosa irritation/sensitization test with treated beer. Unpublished report from Industrial Bio-Test Labs., IBT No. F9655.

Johnson, A.R. and Hewgill, F.R., (1961), The effect of the antioxidants, butylated hydroxyanisole, butylated hydroxytoluene and propylgallate on growth, liver and serum lipids and serum sodium levels of the rats. *Aust. J. Exp. Biol. Med. Sci.*, 39, 353.

Kahn, G., Phamphak, P. and Claman, N.N., (1974), Propylgallate, contact sensitization and orally induced tolerance. *Arch. Dermatol.* 109, 506-509.

Kahl, R. and Hildebrandt, A.G., (1983), Abst. Joint Spring Meeting, Deutsche Pharmakologische Physiologische Gesellschaft, 14-18 March, Mainz 1983.

Kelleher, J., Keaney, N.P., Walker, B.E., Losowsky, M.S. and Dixon, M.S., (1976), Modification of paracetamol hepatotoxicity by antioxidants. *J. Int. Med. Res.* 4 (4), 138-144.

King, D.W., (1964), Comparative effects of certain antioxidants on gestational performance and teratogeny in vitamin E deficient rats. *J. Int. Med. Res.*, 4 (4), 138-144.

King, M.M. and McCay, P.B., (1980), DMBA-induced mammary tumor incidence : effect of propylgallate supplementation in purified diets containing different types and amounts of fat. *Proc. Am. Assoc. Cancer Res.*, 21, 113.

King, M.M. and McCay, P.B., (1981), Studies on liver microsomes of female rats fed purified diets varying in fat content and with and without propylgallate. *Fd. Cosmet. Toxicol.*, 19, 13-17.

King, M.M. and McCay, P.B., (1983), Modulation of tumor incidence and possible mechanisms of inhibition of mammary carcinogenesis by dietary antioxidants. *Cancer Research (Supp.)*, 43, 2485S-2490S.

Koss, G. and Koransky, W., (1982), Enteral absorption and biotransformation of the food additive octylgallate in the rat. *Fd. Chem. Toxic.*, 20, 591-594.

Lehman, A.G., Fitzhugh, O.G., Nelson, A.A. and Woodard, G., (1951), The pharmacological evaluation of antioxidants. *Food Res.*, 3, 197-208.

Life Sciences Research Office, (1973), Report prepared for the FDA. Evaluation of the health aspects of propylgallate as a food ingredient. Contract No. FDA 72-85.

Lindberg, D.C., Keplinger, M.L. and Fancher, O.E., (1970), Ninety-day subacute oral toxicity study with Cold-Pro, Ga-8 in Beagle dogs. Industrial Bio-test Labs. No. C 8472.

Litton Bionetics Inc., (1974), Mutagenic evaluation of compound FDA 71-39, propylgallate. NTIS, PB-245-441.

McDonald-Gibson, W., Saeed, S. and Schneider, C., (1976), Local anticeptive and topical anti-inflammatory effects of propylgallate in rodents. Br. J. Pharmacol., 58, 573-81.

Mirvish, S., Cardesa, A., Wallace, L. and Shubik, P., (1975), Induction of mouse lung adenomas by amines or ureas plus nitrite and by nitroso compounds. Effect of ascorbate, gallic acid, thiocyanate and caffeine. J. Natl. Cancer Inst., 55(3), 633-636.

National Toxicology Program, (1982), Carcinogenesis bioassay of propylgallate (CAS No. 121-799) in F-344/N rats and B6C3F1 mice (feeding study).

Omaye, S.T., Reddy, K.A. and Cross, C.E., (1977), Effect of butylated hydroxytoluene and other antioxidants on mouse lung metabolism. J. Toxicol. Environ. Health, 3 (5-6), 829-836.

Orten, J.M., Kuyper, A.C. and Smith, A.H., (1948), Studies on the toxicity of propylgallate and of antioxidant mixtures containing propylgallate. Food Technol. 2, 308-316.

Osborne, L.C., Peeler, J.T. and Archer, D.L., (1981), Reduction in antiviral activity of human beta interferon by gallic acid. Infection and Immunity, 33, 769-774.

Rosian, M. and Stich, H., (1980), Enhancing and inhibiting effect of propylgallate on carcinogen-induced mutagenesis. J. Environ. Pathol. Toxicol., 4, 159-167.

Scientific Committee for Food, (1978), Report, fifth series, Commission of the European Communities, 13-25.

- Sluis, K.J.H., (1951), The higher alkylgallates as antioxidants. *Food Manuf.*, 26, 99-101.
- Takenaga, K., Honma, Y. and Hozumi, M., (1981), Inhibition of differentiation of mouse myeloid leukemia cells by phenolic antioxidants and  $\alpha$ -tocopherol.
- Tanaka, S., Kawashima, K., Nakaura, S., Nagao, S. and Omori, Y., (1979), Effect of dietary administration of propylgallate during pregnancy on prenatal and postnatal development of rats. *Shokuhin Eiseigakni Zasshi*, 20, 378-384.
- Tollenaar, F.D., (1957), Prevention of rancidity in edible oils and fats with special reference to the use of antioxidants. *Proc. Pacific Sci. Congr.*, 5, 92-103 (pub. 1963), *Pacific Sci. Assoc.*, 9th Bangkok, Thailand.
- Tonkelaar, E.M. den, Verschuuren, H.G., Kroes, R. and Esch, G.J. van, (1968), The influence of propylgallate and  $\alpha$ -tocopherol on the survival of rats during fasting. *Fd. Cosmet. Toxicol.*, 6, 25-31.
- Vanderhoek, J.Y. and Lands, W.E.M., (1973), The inhibition of fatty acid oxygenase of sheep vesicular gland by antioxidants. *Biochem. Biophys. Acta*, 296, 382-385.
- Watanabe, A. and Oshima, Y., (1965), *Agric. Biol. Chem.*, 29, 90.
- Wess, J.A. and Archer, D.L., (1982), Evidence from in vitro murine immunologic assays that some phenolic food additives may function as antipromoters by lowering intracellular cyclic GMP levels (14453). *Proc. Soc. Exp. Biol. Med.*, 170, 427-430.
- WHO, (1962), Joint FAO/WHO Expert Committee on Food additives. WHO, Tech. Rep. series, No. 228, 60-65.
- WHO, (1965), Joint FAO/WHO Expert Committee on Food additives, December 1964. WHO/Food Add/24, 65; WHO Techn. Rep. series, No. 309.
- WHO, (1972), Joint FAO/WHO Expert Committee on Food additives, June 1971. WHO, Food additives Series, No. 3.
- WHO, (1972), Joint FAO/WHO Expert Committee on Food additives, April 1972. WHO, Food additives Series, No. 4, 75-78.
- WHO, (1974), Joint FAO/WHO Expert Committee on Food additives, July 1973. WHO, Food additives Series, No. 5, 183-189.

WHO, (1976), Joint FAO/WHO Expert Committee on Food additives. Toxicological evaluation of certain food additives. WHO, Food additives Series, No. 10, WHO Techn. Rep. Series, No. 559.

WHO, (1980), Evaluation of certain food additives. 24th Report of the Joint FAO/WHO Expert Committee on Food Additives. Technical Report Series, 653, Geneva.

WHO, (1983), Joint FAO/WHO Expert Committee on Food Additives. Specifications for identity and purity. FAO, Food and Nutrition Paper, No. 28.

Yang, C. and Strickhart, F., (1974), Inhibition of hepatic mixed function oxidase activity of propylgallate. *Biochem. Pharmacol.*, 23, 3129-3138.

### BHA

Abe, S. and Sasaki, M., (1977), Chromosome aberrations and sister chromatid exchanges in Chinese hamster cells exposed to various chemicals. *J. Nat. Canc. Inst.*, 58(6), 1635-1641.

Akiyama, M., Kuo, C.H., Hayashi, Y. and Miki, N., (1980), Inhibition of N-methyl-N'-nitro-N-nitrosoguanidine activated guanylate cyclase by anticarcinogenic agents. *Gann.*, 71, 356-361.

Allen, J.R., (1974), Effects of long-term exposure of female non-human primates to butylated hydroxyanisole and butylated hydroxytoluene. *Ann. Rep. of Univ. Wisconsin Food Res. Inst.*, 308-315.

Allen, J.R., (1976), Long-term antioxidant exposure effects on female primates. *Arch. Environm. Health*, 31, 47-50.

Allen, J.R. and Engblom, J.F., (1972), Ultrastructural and biochemical changes in the liver of monkeys given butylated hydroxyanisole and butylated hydroxytoluene. *Food Cosm. Toxicol.*, 10, 769-779.

Altmann, H.J., Wester, P.W., Matthiaschek G., Grunow, W. and van der Heyden, C.A., (1984a), Induction of early lesions in the forestomach of rats by 3-tert-butyl-4-hydroxyanisole (BHA). Submitted for publication.

Altmann, H.J., Wester, P.W., Grunow, W. and van der Heyden, C.A., (1984b), Butylated hydroxyanisole induced stomach lesions in small laboratory animals. *Naunyn Schmiedeberg's Arch. Pharmacol. Suppl. Vol.*, 325, alstr. 110.



Astill, B.D., Fassett, D.W. and Roudabush, R.L., (1960), The metabolism of phenolic antioxidants. The metabolism of butylated hydroxyanisole in the rat. *Biochem. J.*, 75, 543-551.

Astill, B.D., Mills, J., Fassett, D.W., Roudabush, R.L. and Terhaar, C.J., (1962), Fate of butylated hydroxyanisole in man and dog. *J. Agric. Food Chem.*, 10, 315-319.

Bonin, A.M. and Baker, R.S.U., (1980), Mutagenicity testing of some approved food additives with the Salmonella microsome assay. *Food Technol. Austr.*, 32(12), 608-611.

Brown, W.D., Johnson, A.R., O'Halloran, M.W., (1959), The effect of the level of dietary fat on the toxicity of phenolic antioxidants. *Austr. J. Exp. Biol.*, 37, 533-548.

Bunnell, R.H., Matterson, L.D., Singsen, E.P., Potter, L.M., Kozeff, A. and Jungherr, E.L., (1955), Studies on encephalomalacia in the chick. The influence of feeding or injecting various tocopherols and other antioxidants on the incidence on encephalomalacia. *Poultry Sci.*, 34, 1068-1075.

Busck, J., (1984), Final report on the safety assessment of butylated hydroxyanisole. *J.A.M.College of Tox.*, 3,(5) 83-146.

Clegg, D.J., (1965), Absence of teratogenic effects of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) in rats and mice. *Food Cosmet. Toxicol.*, 3, 387-403.

Clayson, D.B., (1984), Canadian studies on BHA. Transcript Toxicology Forum Meeting, Washington.

Cloninger, P. and Novey, H., (1974), The acute effects of butylated hydroxyanisole ingestion in asthma and rhinitis of unknown etiology. *Ann. Allergy*, 32, 131-133.

Craven, P.A. and De Rubertis, F.R., (1977), Inhibition of retinol and butylated hydroxyanisole of carcinogen mediated increases in guanylate cyclase activity and guanosine-3:5-monophosphate accumulation. *Cancer Res.*, 37, 4088-4097.

Dacre, J.C., Denz, F.A. and Kennedy, T.H., (1956), The metabolism of butylated hydroxyanisole in the rabbit. *Biochem. J.*, 64, 777-782.

Dacre, J.C., (1958), (no title) Ann. Rep. Med. Res. Council, NZ 32.

Daniel, J.W., Gage, J.C., Jones, D.I. and Stevens, M.A., (1967), Excretion of butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA) bij man. Food Cosmet. Toxicol., 5, 475-479.

Commission of the European Communities, (1983), Report of the Scientific Committee for Food. Fourteenth Series, (EUR 8752 EN).

Degré, R. and Saheb, S.A., (1982), Butylated hydroxyanisole as a possible mutagenic agent. FEMS Microbiology Letters, 14, 183-186.

El-Rashidy, R. and Niazi, S., (1983), A new metabolite of butylated hydroxyanisole in man. Biopharm. Dr., 4, 389-396.

Fabrizio, D.P.A., (1974), Mutagenic evaluation of compound FDA, 71-24 : butylated hydroxyanisole. Unpublished report from Litton Bionetics.

Francois, A.C. and Pehet, A., (1960), Influence of the ingestion of antioxidants on the composition of certain tissues and on the stability of the reserve fat of pigs and pullets. Ann. Inst. Natl. Research Agron. Sci., D 9, 195-208.

Gage, J.C., (1966), The metabolism of phenolic antioxidants. Fette, Seifen, Anstrichm., 68, (11), 951-954.

Golder, W.S., Ryan, A.J. and Wright, S.E., (1962), The urinary excretion of tritiated butylated hydroxyanisole and butylated toluene in the rat. J. Pharm. Pharmacol., 14, 268-271.

Grunow, W., (1984), Short-term studies with BHA. Transcript Toxicology Forum Meeting, Washington.

Hansen, E. and Mayer, O., (1978), A study of the teratogenicity of butylated hydroxyanisole on rabbit. Toxicology, 10, 195-201.

Hansen, E.V., Meyer, O. and Olsen, P., (1982), Study on toxicity of butylated hydroxyanisole (BHA) in pregnant gilts and their foetuses. Toxicology, 23, 79-83.

Hayashi, Y., (1984), Japanese view on phenolic antioxidants and most recent findings. Transcript Toxicology Forum Meeting, Washington.

Hodge, H.C., Fassett, D.W., Maynard, E.A., Douns, W.L. and Coye, R.D. Jr., (1964), Chronic feeding studies of butylated hydroxyanisole in dogs. *Toxicol. Appl. Pharm.*, 6, (5), 512-519.

International Life Science Institute, (1984), Butylated hydroxyanisole (monograph). Report of Antioxidant Technical Committee, Washington D.C.

Ishidate, M. and Odashima, S., (1977), Chromosome tests with 134 compounds on chinese hamster cells in vitro. A screening for chemical carcinogens. *Mutat. Res.*, 48, 337-354.

Ito, N., Hirose, M., Kurata, Y., Ikawa, E., Mera, Y. and Fukushima, S., (1984), Induction of forestomach hyperplasia by crude butylated hydroxyanisole a mixture of 3-tert and 2-tert isomers in Syrian golden hamsters is due to 3-tert butylated hydroxyanisole. *Gann.*, 75, 471-474.

Ito, N., Fukushima, S., Imaida, K., Sakata, T. and Masui, T., (1983), Induction of papilloma in the forestomach of hamsters by butylated hydroxyanisole. *Gann.*, 74, 459-461.

Ito, N., (1982), Carcinogenicity of butylated hydroxyanisole in F-344 rats. Prepared for Japanese Food Sanitation Council.

Ito, N., Hariwara, A., Shibata, M., Ogiso, T. and Fukushima, S., (1982), Induction of squamous cell carcinoma in the forestomach of F-344 rats treated with butylated hydroxyanisole. *Gann.*, 73, 332-334.

Ito, N., Hagiwara, A., Shibata, N., Ogiso, T. and Fukushima, S., (1982), Induction of squamous cell carcinoma in the forestomach of F-344 rats treated with butylated hydroxyanisole. *Gann.*, 73, 332-334.

Ito et al., (1985?), Unpublished data.

Iverson, F., Lok, E., Nera, E., Karpinski, K. and Clayson, D.B., (1985a), A 13-week feeding study of butylated hydroxyanisole : The subsequent regression of the induced lesions in male Fischer 344 rat forestomach epithelium. *Toxicol.*, 35, 1-11.

Iverson, F., Truelove, J., Nera, E., Wong, J., Lok, E. and Clayson, D.B., (1985b), An 85-day study of butylated hydroxyanisole in the Cynomolgus monkey. *Cancer Lett.*, 26, 43-50.

Joint FAO/WHO Expert Committee on Food Additives, (1962), Evaluation of the toxicity of a number of antimicrobials and antioxidants. FAO Nutr. Rep. Ser. No. 31, WHO Techn. Rep. Ser., No. 228.

Joint FAO/WHO Expert Committee on Food Additives, (1972), A review of the technological efficacy of some antioxidants and synergists. FAO Nutr. Rep. Ser., No. 50, WHO Techn. Rep. Ser., No. 448.

Joint FAO/WHO Expert Committee on Food Additives, (1974), Toxicological evaluation of some food additives including anticaking agents, antimicrobials, antioxidants, emulsifiers and thickening agents. FAO Nutr. Rep. Ser., No. 53, WHO Techn. Rep. Ser., No. 539.

Joint FAO/WHO Expert Committee on Food Additives, (1976), Toxicological evaluation of certain food additives. WHO Food Add. Ser., No. 10, WHO Techn. Rep. Ser., No. 599.

Joint FAO/WHO Expert Committee on Food Additives, (1980), Toxicological evaluation of certain food additives. WHO Food Add. Ser., No. 15, WHO Techn. Rep. Ser., No. 653.

Joint FAO/WHO Expert Committee on Food Additives, (1983), Toxicological evaluation of certain food additives. WHO Food Add. Ser., No. 18.

Joner, P.R., (1977), Butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT) and ethoxyquin (EMQ) tested for mutagenicity. *Acata Vet. Scand.*, 18, 187-193.

Kim, H.L. and Jones, L.P., (1982), Protective effects of butylated hydroxyanisole, ethoxyquin and disulfiram on acute pyrrolizidine alkaloids poisoning in mice. *Res. Commun. Chem. Path. Pharmacol.*, 36, 341-344.

King, M.M., Bailey, D.M., Gibson, D.D., Pitha, J.V. and McCay, P.B., (1979), Incidence and growth of mammary tumours induced by 7,12-dimethylbenz(a)anthracene as related to the dietary content of fat and antioxidant. *J. Nat. Canc. Inst.*, 63, 657-663.

Kurechi, T., Kikugawa, K. and Kato, T., (1980), The butylated hydroxyanisole nitrite reaction. Effects on N-nitrosodimethylamine formation in model systems. *Chem. Pharm. Bull.*, 28, 1314-1317.

Lehman, A.J., Fitzhugh, O.G., Nelson, A.A. and Woodward, G., (1951), The pharmacological evaluation of antioxidants. *Advanc. Food Res.*, 3, 197-208.

Litton Bionetics, (1975), Mutagenic evaluation of compound FDA, 71-24, butylated hydroxyanisole. Submitted to FDA under contract, 223-74-2104. NTIS No. PB 245-510.

McCay, P.B., King, M.M. and Pitha, J.V., (1981), Evidence that the effectiveness of antioxidants as inhibitors of 7,12-dimethylbenz(a)anthracene induced mammary tumours in a function of dietary fat composition. *Canc. Res.*, 41, 3745-3748.

- McCay, P.B., King, M.M., Rikaus, L.E. and Pitha, J.V., (1980), Interaction between dietary fats and antioxidants on DMBA induced mammary carcinomas and on AAF induced hyperplastic nodules and hepatomas. *J. Environm. Path.*, 3, 451-465.
- McCormick, D.L. and Moon, R.C., (1983), Inhibition of rat mammary carcinogenesis by pre- and postcarcinogen administration of antioxidants. *Proc. Amer. Assoc. Cancer Res.*, 24, 87.
- Minigishi, K.I., Watanabe, M. and Yamaha, T., (1981), Distribution of butylated hydroxyanisole and its conjugates in the tissues of rats. *Chem. Pharm. Bull.*, 29, 1377-.
- Miranda, C.L., Buhler, D.R., Ramsdell, H.S., Cheeke, P.R. and Schmitz, J.A., (1982), Modification of chronic hepatotoxicity of pyrrolizidine (Senecio) alkaloids by butylated hydroxyanisole and cysteine. *Toxicol. Lett.*, 10, 177-182.
- Miranda, C.L., Reed, R.L., Cheeke, P.R. and Buhler, D.R., (1981), Protection effects of butylated hydroxyanisole against the acute toxicity of monocrotaline in mice. *Toxicol. Appl. Pharmacol.*, 59, 424-430.
- Miyagi, M. and Goodheart, C.R., (1976), Effects of butylated hydroxyanisole in Drosophila melanogaster. *Mutat. Res.*, 40, 37-42.
- Nera, E.A., Lok, E., Iverson, F., Ormsby, E., Karpinski, K.F. and Clayson D.B., (1984), Short-term pathological and proliferative effects of butylated hydroxyanisole and other phenolic antioxidants in the forestomach of Fischer 344 rats. *Toxicol.*, 32, 197-213.
- Olsen, P., (1983), The carcinogenic effect of BHA on the stratified epithelium of the stomach in rat versus pig. *Cancer Lett.*, 21, 115-116.
- Pamukcu, A.M., Yalciner, S. and Bryan, G.T., (1977), Inhibition of carcinogenic effect of bracken fern (Pteridium aquilinum) by various chemicals. *Cancer*, 40, 2450-2454.
- Peraino, C., Fry, R.J.M. and Staffeldt, E., (1971), Reduction and enhancement of phenobarbital of hepatocarcinogenesis in the rat by 2-acetylaminofluorene. *Canc. Res.*, 31, 1506-.
- Roed-Peterson and Hjorth, N., (1976), Contact dermatitis from antioxidants hidden sensitizers in topical medications and foods. *Brit. J. Derm.*, 94, 233-241.
- Shelef, L.A. and Chin, B., (1982), Effect of phenolic antioxidants on the mutagenicity of aflatoxin B-1. *Appl. and Environm. Microbiol.*, 40(6), 1039-1043.

Slaga, T.J. and Bracken, W.M., (1977), The effects of antioxidants on skin tumour inhibition and aryl hydrocarbon hydroxylase. *Canc. Res.*, 37, 1631-1635.

Slaga, T.J., Fisher, S.M., Weeks, C.E. and Klein-Szanto, A.J.P., (1981), Cellular and biochemical mechanisms of mouse skin tumour promoters. *Reviews in Biochem. Toxicol.*, 3, 231-282.

Stokes, J.D. and Scudder, C.L., (1974), The effect of butylated hydroxyanisole and butylated hydroxytoluene on behavioural development of mice. *Dev. Psychobiol.*, 7(4), 343-350.

Telford, I.R., Woodruff, C.S. and Linford, R.H., (1962), Fetal resorption in the rat influenced by certain antioxidants. *Am. J. Anat.*, 110, 29-36.

Tomii, S. and Aoki, Y., (1982), Chronic toxicity study in BHA. Unpublished summary of July 20. Report prepared for the Food Chemistry Division of Min. of Health and Welfare, Japan, March, (1977).

Report of the UK Ministry of Agriculture, Fisheries and Food, submitted to the Scientific Committee for Food of the EEC. Dated : London, 20 January, 1983.

US Food and Drug Administration. cf International Life Science Institute report, 10-1-1984 (page 16). See also Food Chemical News, February 27, 1984, page 31.

Valencia, R. and Abrahamson, S., (1982), Personal communication.

Vorhees, C., Brunner, R., Wooten, V. and Butcher, R., (1979), Psychotoxicity of selected food additives and related compounds. Unpublished report from Children, Hospital Research Foundation's, Cincinnati, submitted to WHO by the US Food and Drug Administration.

Wattenberg, L.M. and Spornins, V.L., (1979), Inhibitory effects of butylated hydroxyanisole on methylazoxy methanol acetate-induced neoplasia of the large intestine and on nicotinamide adenine dinucleotide dependent alcohol dehydrogenase activity in mice. *J. Nat. Canc. Inst.*, 63, 219-222.

Wattenberg, L.W., (1973), Inhibition of chemical carcinogen induced pulmonary neoplasia by butylated hydroxyanisole. *J. Nat. Canc. Inst.*, 50, 1541-1544.

Wattenberg, L.W., (1972), Inhibition of carcinogenic and toxic effects of polycyclic hydrocarbons by phenolic antioxidants and ethoxyquin. *J. Nat. Canc. Inst.*, 48, 1425-1430.

Wilder, O.H.M., Ostby, P.C. and Gregory, B.R., (1960), Effect of feeding butylated hydroxyanisole to dogs. *J. Agric. Food Chem.*, 8, 504-506.

Witschi, H.P., (1980), Unpublished observation. cf I.L.S.I. file on BHA.

Witschi, H.P., Hakkinen, P.J. and Kehrer, J.P., (1981), Modification of lung tumour development in A/J mice. *Toxicology*, 21, 37-45.

Witschi, H.P. and Doherty, D.G., (1984), Butylated hydroxyanisole and lung tumour development in A/J mice. *Fundam. Appl. Toxicol.*, 4, 795-801.

Witschi, H.P. and Kehrer, J.P., (1982), Adenoma development in mouse lung following treatment with possible promoting agents. *J. Am. College Toxicol.*, 1, 171-184.

Yokoro, (1982), Personal communication.

#### BHT

Adamson, I.Y.R., Bowden, D.H., Cote, M.G. and Witschi, H., (1977), Lung injury induced by butylated hydroxytoluene : cytodynamic and biochemical studies in mice. *Lab. Invest.*, 36, 26-32.

Akagi, M. and Aoki, I., (1962), Investigations on food additives. 6. Communication. Metabolism of 2,6-di-tert-butyl-p-cresol in the rabbit. (1) Determination and paper chromatography of a metabolite. *Chem. Pharm. Bull.*, 10, 101-105.

Allen, J.R., (1976), Effects of long-term exposure to antioxidants in female non-human primates. *Arch. Environ. Hlth*, 31, 47-50.

Allen, J.R. and Engblom, J.F., (1972), Ultrastructural and biochemical changes in the liver of monkeys given butylated hydroxytoluene and butylated hydroxyanisole. *Fd. Cosmet. Toxicol.*, 10, 769-779.

Aoki, I. (1962) Investigations of food additives. 7. Communication. Metabolism of 2,6-di-tert-butyl-p-cresol in the rabbit. (2) Isolation of a metabolite. *Chem. Pharm. Bull.*, 10, 105-112.

Branen, A.L., (1975), Toxicology and biochemistry of butylated hydroxyanisole and butylated hydroxytoluene. *J. Am. Oil Chem. Soc.* 52, 54-63.

Brooks, T.M., Hunt, P.F., Thorpe, E. and Walker, A.T., (1974), Unpublished results cited in Fed. Register, 42, (104) 27603-27606.

Brown, W.D., Johnson, A.R. and O'Halloran, M.W., (1959), The effect of the level of dietary fat on the toxicity of phenolic antioxidants. Aust J. Exp. Biol. Med. Sci., 37, 533-547.

Bruce W.R. and Heddle J.A., (1979), The mutagenic activity of 61 agents as determined by the micronucleus, Salmonella and sperm abnormality assays. Can. J. Genet. Cytol, 21, 319.

CEC, (1984), Report of an ad hoc working group on the safety of antioxidants, 25-26 October, 1984. Commission of the European Communities. Document III/1682/84, Brussels, December, 1984.

Cha, Y.-N. and Heine, H.S., (1982), Comparative effects of dietary administration of 2(3)-tert-butyl-4-hydroxyanisole and 3,5-di-tert-4-hydroxytoluene on several hepatic enzyme activities in mice and rats. Cancer Res., 42, 2609-2615.

Clapp, N.K., Bowles, N.D., Satterfield, L.C. and Klima, W.C., (1979), Selective protective effect of butylated hydroxytoluene against 1,2-dimethylhydrazine carcinogenesis in BALB/c mice. J. Natl Cancer Inst., 63, 1081.

Clapp, N.K., Tyndall, R.L., Cumming, R.B. and Otten, J.A., (1974), Effects of butylated hydroxytoluene alone or with diethylnitrosamine in mice. Fd. Cosmet. Toxicol., 12, 367-371.

Clapp, N.K., Tyndall, R.L., Satterfield, L.C., Klima, W.C. and Bowles, N.D., (1978), Selective sex-related modification of diethylnitrosamine-induced carcinogenesis in BALB/c mice by concomitant administration of butylated hydroxytoluene. J. Natl. Cancer Inst., 61, 177.

Clegg, D.J., (1965), Absence of teratogenic effect of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) in rats and mice. Fd. Cosmet. Toxicol., 3, 387-403.

Collings, A.J. and Sharratt, M., (1970), The BHT content of human adipose tissue. Fd. Cosmet. Toxicol., 8, 409-412.

Creaven, P.J., Davies, W.H. and Williams, R.T., (1966), The effect of butylated hydroxytoluene, butylated hydroxyanisole and octyl gallate upon liver weight and biphenyl 4-hydroxylase activity in the rat. J. Pharm. Pharmac., 18, 485-489.



Cumming, R.B., Walton, M.F., Kelly, E.M. and Russel, W.L., (1983), Reported in Adler I-D, *Mutat. Res.*, 115, 293-321.

Daniel, J.W. and Gage, J.C., (1965), The absorption and excretion of butylated hydroxytoluene (BHT) in the rat. *Fd. Cosmet. Toxicol.*, 3, 405-415.

Daniel, J.W., Gage, J.C., Jones, D.I. and Stevens, M.A., (1967), Excretion of butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA) in man. *Fd. Cosmet. Toxicol.*, 5, 475-479.

Daniel, J.W., Gage, J.C. and Jones, D.I., (1968), The metabolism of 3,5-di-tert-butyl-4-hydroxytoluene in the rat and in man. *Biochem. J.*, 106, 783-790.

Day, A.J., Johnson, A.R., O'Halloran, M.W. and Schwartz, C.J., (1959), The effect of the antioxidant butylated hydroxytoluene on serum lipid and glycoprotein levels in the rat. *Aust. J. Exp. Biol. Med. Sci.*, 37, 295-306.

Deichmann, W.B., Clemmer, J.J., Rakoczy, R. and Bianchine, J., (1955), Toxicity of di-tertiary-butyl-methyl-phenol. *AMA Arch. Ind. Hlth*, 11, 93-101.

Denz, F.A. and Llaurodo, J.G., (1957), Some effects of phenolic antioxidants on sodium and potassium balance in the rabbit. *Br. J. Exp. Pathol.*, 38, 315-324.

El-Rashidy and Niazi, S., (1980), Comparative pharmacokinetics of butylated hydroxyanisole and butylated hydroxytoluene in rabbits. *J. Pharm. Sci.*, 69, 1455-1457.

Epstein, S.S. and Shafner, H., (1968), Chemical mutagens in the human environment. *Nature*, 219, 385-387.

Food and Drug Research Labs Inc., (1972), Teratologic evaluation of FDA 71-25, (butylated hydroxytoluene - Ionol). NTIS PB-221-782.

Food and Drug Research Labs Inc., (1977), Teratologic evaluation of compound FDA 71-25, butylated hydroxytoluene (Ionol) in rabbits. NTIS PB-267-201.

Ford, S.M., Hook, J.B. and Bond, J.T., (1980a), The effects of butylated hydroxyanisole and butylated hydroxytoluene on renal function in the rat. I. Effects on fluid and electrolyte excreted. *Fd. Cosmet. Toxicol.*, 18, 5-20.

Ford, S.M., Hook, J.B. and Bond, J.T., (1980b), The effects of butylated hydroxyanisole and butylated hydroxytoluene on renal function in the rat. II. Effects on organic acid and base transport. *Fd. Cosmet. Toxicol.*, 18, 21-26.

Frawley, J.P., Kohn, F.E., Kay, J.H. and Calandra, J.C., (1965), Progress report on multigeneration studies in rats fed butylated hydroxytoluene (BHT). *Fd. Cosmet. Toxicol.*, 3, 377-386.

Gaunt, I.F., Feuer, G. Fairweather, F.A. and Gilbert, D., (1965), Liver response tests. IV. Application to short-term feeding studies with butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA). *Fd. Cosmet. Toxicol.*, 3, 433-443.

Goater, T.D., Kenyon, A.J. and Hurst, E.W., (1964), The subacute toxicity of Topanol<sup>(R)</sup> BHT. Unpublished report submitted to WHO by Imperial Chemical Industries Ltd, UK.

Harman, D., Curtis, H.J. and Tilley, J., (1970), Chromosomal aberrations in liver cells of mice fed free radical reaction inhibitors. *J. Gerontol.*, 25, 17-19.

Hiraga, K., (1977a), Mutagenicity test of eight antioxidants, including 3,5-di-tert-butyl-4-hydroxytoluene (BHT) with bacterial systems. Tokyo Metropolitan Research Laboratory of Public Health 32, 13 pp.

Hiraga, K., (1977b), Cytogenetic studies and dominant lethal test in mice and rats after long-term administration of dibutylhydroxytoluene (BHT). Tokyo Metropolitan Research Laboratory of Public Health 32, 12 pp.

Hirose, M., Shibata, M., Hagiwara, A., Imaida, K. and Ito, N., (1981), Chronic toxicity of butylated hydroxytoluene in Wistar rats. *Fd. Cosmet. Toxicol.*, 19, 147-151.

Imaida, K., Fukushima, S., Shirai, T., Ohtani, M., Nakanishi, K. and Ito, N., (1983), Promoting activities of butylated hydroxyanisole and butylated hydroxytoluene on 2-stage urinary bladder carcinogenesis and inhibition of gamma-glutamyl transpeptidase-positive foci development in the liver of rats. *Carcinogenesis*, 4, 895-899.

JECFA, (1983), Evaluation of certain food additives and contaminants. 27th Report of the Joint FAO/WHO Committee on Food Additives, Technical Report Series 696, WHO, Geneva.

Johnson, A.R., (1965), A re-examination of the possible teratogenic effects of butylated hydroxytoluene (BHT) and its effect on the reproductive capacity of the mouse. *Fd. Cosmet. Toxicol.*, 3, 371-375.

Johnson, A.R. and Hegwill, F.R., (1961), The effect of the antioxidants, butylated hydroxyanisole, butylated hydroxytoluene and propyl gallate on growth, liver and serum lipids, and serum sodium levels of the rat. *Aust. J. Exp. Biol. Med. Sci.*, 39, 353-360.

Joner, P.R., (1977), Butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT) and ethoxyquin (EMQ) tested for mutagenicity. *Acta Vet. Scand.*, 18, 187-193.

Kahl, R., (1984), Synthetic antioxidants : biochemical actions and interference with radiation, toxic compounds, chemical mutagens and chemical carcinogens. *Toxicology*, 33, 185-228.

Kamra, O.P., (1973), Radiosensitising property of butylated hydroxytoluene in *Drosophila* sperm. *Int. J. Radiat. Biol.*, 23, 295-297.

Karplyuk, I.A., (1959), Toxicological characteristics of phenol antioxidants in nutrient fats (acute and subacute experiments). *Vop. Pitan.*, 18, 24-29.

Kawano, S., Nakao, T. and Hiraga, K., (1980), Species and strain differences in the butylated hydroxytoluene (BHT) producing induction of hepatic drug oxidation enzymes. *Japan J. Pharmacol.*, 30, 861-870.

Kawano, S., Nakao, T. and Hiraga, K., (1981), Induction of hepatic microsomal monooxygenases in female rats given various substituted phenols and hydroquinones. *Japan J. Pharmacol.*, 31, 459-462.

King, M.M., McKay, P.B. and Kosanke, S.D., (1981), Comparison of the effects of butylated hydroxytoluene on N-nitrosomethylurea and 7,12-dimethyl-benz-a-anthracene-induced mammary tumours. *Cancer Lett.*, 14, 219-226.

Litton Bionetics Inc., (1975), Mutagenic evaluation of butylated hydroxytoluene. NTIS PB-245-487.

Maeura, Y. and Williams, G.M., (1984), Enhancing effect of butylated hydroxytoluene on the development of liver altered foci and neoplasms induced by N-2-fluorenylacetamide in rats. *Fd. Cosmet. Toxicol.*, 22, 191-198.

Marino, A.A. and Mitchell, J.T., (1972), Lung damage in mice following intraperitoneal injection of butylated hydroxytoluene. *Proc. Soc. Exp. Biol. Med.*, 140, 122-125.

Matsuo, M., Mihara, K., Okuno, M., Ohkawa, H. and Miyamoto, J., (1984), Comparative metabolism of 3,5-di-tert-butyl-4-hydroxytoluene (BHT) in mice and rats. *Fd. Chem. Toxicol.*, 22, 345-354.

McCormick, D.L., Major, N. and Moon, R.C., (1984), Inhibition of 7,12-dimethylbenz-a-anthracene-induced rat mammary carcinogenesis by concomitant or postcarcinogen antioxidant exposure. *Cancer Res.*, 44, 2858-2863.

Meyer, O., Blom, L. and Olsen, P., (1978), Influence of diet and strain of rat on kidney damage observed in toxicity studies. *Arch. Toxicol. Suppl.*, 1, 355-358.

Meyer, O. and Hansen, E., (1980), Behavioural and developmental effects of butylated hydroxytoluene dosed to rats in utero and in the lactation period. *Toxicology*, 16, 247-258.

Mizutani, T., Ishida, I., Yamamoto, K. and Tajima, K., (1982), Pulmonary toxicity of butylated hydroxytoluene and related alkylphenols : structural requirements for toxic potency in mice. *Toxicol. appl. Pharmacol.*, 62, 273-281.

NIH, (1979), Bioassay of butylated hydroxytoluene (BHT) for possible carcinogenicity. NCI-CG-TR-150.

Olsen, P., Bille, N. and Meyer, O., (1983), Hepatocellular neoplasms in rats induced by butylated hydroxytoluene (BHT). *Acta pharmacol. toxicol.*, 53, 433-434.

Omaye, S.T., Reddy, K.A. and Cross, C.E., (1977), Effect of butylated hydroxytoluene and other antioxidants on mouse lung metabolism. *J. Toxicol. Environ. Hlth.*, 3, 829-836.

Paschin, Y.V. and Bahitove, L.M., (1984), Inhibition of mutagenicity of benzo(a)-pyrene in the V79/HGPRT system by bioantioxidants. *Mutat. Res.*, 137, 57-59.

Peranio, C., Fry, R.J.M., Staffeldt, E. and Christopher, J.P., (1977), Enhancing effects of phenobarbitone and butylated hydroxytoluene on 2-acetylaminofluorene-induced hepatic tumorigenesis in the rat. *Fd. Cosmet. Toxicol.*, 15, 93-96.

Prasad, O. and Kamra, O.P., (1974), Radiosensitisation of Drosophila sperm by commonly used food additives, butylated hydroxyanisole and butylated hydroxytoluene. *Int. J. Radiat. Biol.*, 25, 67-72.

Roebuck, B.D., MacMillan, D.L., Bush, D.M. and Kensler, T.W., (1984), Modulation of azaserine-induced pancreatic foci by phenolic antioxidants in rats. *J. Natl. Cancer Inst.*, 72, 1405-1409.

Saccone, G.T.P. and Pariza, M.W., (1978), Effects of dietary butylated hydroxytoluene and phenobarbital on the activities of ornithine decarboxylase and thymidine kinase in rat liver and lung. *Cancer Lett.*, 5, 145-152.

Sahel, W. and Witschi, H., (1975), Lung growth in mice after a single dose of butylated hydroxytoluene. *Toxicol. appl. Pharmacol.*, 33, 309-319.

SCF, (1978), Reports of the Scientific Committee for Food. Fifth Series. Commission of the European Communities, pp 13-15.

Sciorra, L.J., Kaufmann, B.N. and Maier, R., (1974), The effects of butylated hydroxytoluene on the cell cycle and chromosome morphology of phyto-haemagglutinin-stimulated leucocyte cultures. *Fd. Cosmet. Toxicol.*, 12, 33.

Shirai, T., Hagiwara, A., Kurata, Y., Shibata, M., Fukushima, S. and Ito, N., (1982), Lack of carcinogenicity of butylated hydroxytoluene on long-term administration to B6C3F<sub>1</sub> mice. *Fd. Chem. Toxicol.*, 20, 861-865.

Sondergaard, D. and Olsen, P., (1982), The effect of butylated hydroxytoluene (BHT) on the rat thyroid. *Toxicol. Lett.*, 10, 239-244.

Sporn, A. and Schöbesch, O., (1961), Research on the toxicity of butylated hydroxytoluene. *ig. Microbiol. Epidem. Buc.*, 9, 113-119.

Stanford Research Institute, (1972), Study of the mutagenic effects of Ionol C.P. (butylated hydroxytoluene) (71-25). NTIS PB-221-827.

Stanford Research Institute, (1977), Study of the mutagenic effects of butylated hydroxytoluene (71-25) by the dominant lethal test in rats. NTIS PB-278-026.

Suzuki, H., Hiraga, K. and Nakao, T., (1975), Mechanism of haemorrhage in rats fed with butylated hydroxytoluene (BHT) and linear alkylbenzene sulfonate. *Tokyo Eiken Nempo*, 26, 49-52.

Tajima, K., Yamamoto, K. and Mizutani, T., (1981), No title. *Chem. Pharm. Bull.*, 29, 3738.

Takahashi, O., Hayashida, S. and Hiraga, K., (1980), Species differences in the haemorrhagic response to butylated hydroxytoluene. *Fd. Cosmet. Toxicol.*, 18, 229-235.

Takahashi, D. and Hiraga, K., (1978a), Dose response study of haemorrhagic death by dietary butylated hydroxytoluene (BHT) in male rats. *Toxicol. appl. Pharmacol.*, 43, 399-406.

Takahashi, O. and Hiraga, K., (1978b), Effect of low levels of butylated hydroxytoluene on the prothrombin index of male rats. *Fd. Cosmet. Toxicol.*, 16, 475-477.

Takahashi, O. and Hiraga, K., (1984), Effects of dietary butylated hydroxytoluene on functional and biochemical properties of platelets and plasma preceding the occurrence of haemorrhage in rats. *Fd. Chem. Toxicol.*, 22, 97-103.

Ulland, B.M., Weisburger, J.H., Yamamoto, R.S. and Weisburger, E.K., (1973), Antioxidants and carcinogenesis: butylated hydroxytoluene but not diphenyl-p-phenylene-diamine, inhibits cancer induction by N-2-fluorenylacetylamide and by N-hydroxy-2-fluorenylacetylamide in rats. *Fd. Cosmet. Toxicol.*, 11, 199-207.

Wattenberg, L.W., (1972), Inhibition of carcinogenic and toxic effects of polycyclic aromatic hydrocarbons by phenolic antioxidants and ethoxyquin. *J. Natl. Cancer Inst.*, 48, 1425-1430.

Weisburger, E.K., Evarts, R.P. and Wenk, M.L., (1977), Inhibitory effect of butylated hydroxytoluene (BHT) on intestinal carcinogenesis in rats by azoxymethane. *Fd. Cosmet. Toxicol.*, 15, 139-141.

Wess, J.A. and Archer, D.L., (1982), Evidence from *in vitro* murine immunologic assays that some phenolic food additives may function as antipromoters by lowering intracellular cyclic GMP levels. *Proc. Soc. Exp. Biol. Med.*, 170, 427-430.

Wiebe, L.I., Mercier, J.R. and Ryan, A.J., (1978), Urinary metabolites of 3,5-di-(1-<sup>13</sup>C)methyl-1-methylethyl)-4-hydroxytoluene (BHT-<sup>13</sup>C) in man. *Drug Metab. Dispos.*, 6, 296-302.

Williams, G.M., Mauera, Y. and Weisburger, J.H., (1983), Simultaneous inhibition of liver carcinogenicity and enhancement of bladder carcinogenicity of N-2-fluorenylacetylamide by butylated hydroxytoluene. *Cancer Lett.*, 19, 55-60.

Williams, G.M., Shimada, T., McQueen, C., Tong, C. and Brat, S.V., (1984), Lack of genotoxicity of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT). *Society of Toxicology Abstracts*, Atlanta, March 12-16, 1984.

Witschi, H.P., (1981), Enhancement of tumour formation in mouse lung by dietary butylated hydroxytoluene. *Toxicology*, 21, 95-104.

Witschi, H.P., Hakkinen, P.J. and Kehrer, J.P., (1981), Modification of lung tumour development in A/J mice. *Toxicology*, 21, 37-45.

Witschi, H.P. and Kehrer, J.P., (1982), Adenoma development in mouse lung following treatment with possible promoting agents. *J. Am. Coll. Toxicol.*, 1, 171.

Witschi, H.P. and Lock, S., (1979), Enhancement of adenoma formation in mouse lung by butylated hydroxytoluene. *Toxicol. appl. Pharmacol.*, 50, 291-400.

Yamamoto, K., Tajima, K. and Mizutani, T., (1979), Identification of new metabolites of butylated hydroxytoluene (BHT) in rats. *J. Pharm. Dyn.*, 2, 164-168.

### TBHQ

Anonymous, (1968a), Determination of the stability and tertiary butyl hydroquinone content of rat and dog fat extracts. Unpublished technical report No. 495-F submitted to the World Health Organization by Eastman Chemical products, Inc.

Anonymous, (1968b), Two-year chronic feeding studies with tertiary butyl hydroquinone (TBHQ) in dogs. Unpublished report from the Food and Drug Research Labs, Inc. submitted to the World Health Organization by Eastman Chemical Products, Inc.

Astill, B.D., Blakeley, R.V. and Cantor, E.E., (1967a), The metabolic fate of TBHQ in rats and dogs of TBHQ-<sup>14</sup>C in rats. Unpublished report of the Biochemical Laboratory, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Astill, B.D., Cantor, E.E. and McEwan, D.B., (1967b), Long-term feedings of TBHQ levels and autopsied fat analyses. Unpublished report from the Biochemistry Laboratory, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Astill, B.D., Cantor, E.E., Ely, T.S., Jones, W.H. and Uskavitch, R.J., (1967c), The oral ingestion of t-butylhydroquinone (TBHQ) by humans; clinical observations and metabolic fate. Unpublished report from the Laboratory of Industrial Medicine, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Astill, B.D. and Walton, D.A., (1968), Distribution of radioactivity in pregnant rats receiving <sup>14</sup>C-labeled TBHQ. Unpublished report from the Biochemistry Laboratory, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Astill, B.D., Blakeley, R.V., Cantor, E.E., Tischer, K.S., Walton, D.A., McEwan, D.B., Jones, W.H. and Ely, T.S., (1968), Biochemical studies on Tert-Butylhydroquinone (TBHQ). A Summary. Unpublished report from the Laboratory of Industrial Medicine, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Astill, B.D. and Jones, B.E., (1969), Long-term feedings of TBHQ to rats and dogs : levels of TBHQ in tissues and organs of autopsied animals. Unpublished report from the Biochemistry Laboratory, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Fassett, D.W., Terhaar, C.J. and Astill, B.D., (1968), Summary of the safety evaluation of monotertiary butyl hydroquinone. Unpublished report from the Laboratory of Industrial Medicine, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Krasavage, W.J. and Terhaar, C.J., (1970), The reproductive performance of rats fed monotertiary butyl hydroquinone : a single generation study. Unpublished report from the Toxicology Laboratory, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Terhaar, C.J. and Krasavage, W.J., (1968a), The reproductive performance of rats fed monotertiary butyl hydroquinone. Unpublished report from the Toxicology Laboratory, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Terhaar, C.J. and Krasavage, W.J., (1968b), Monotertiary butyl hydroquinone (TBHQ) in heated and unheated cottonseed oil. A six-month dietary feeding study in rats. Unpublished report from the Toxicology Laboratory, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Terhaar, C.J., Vis, E.A. and Kosel, H.J., (1968a), Acute oral toxicity of monotertiary butyl hydroquinone (TBHQ). Unpublished report from the Laboratory of Industrial Medicine, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Terhaar, C.J., Krasavage, W.J., Wolf, G.L. and Leonard, W.J., (1968b), Study of the tolerance of rats to monotertiary butyl hydroquinone in the diet. Final report at 20 months. Unpublished report from the Toxicology Laboratory, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Tischer, K.S. and Walton, D.A., (1968), Dietary feeding of TBHQ and related compounds to rats and dogs : the response of liver processing enzymes and liver glucose-6-phosphatase activity. Unpublished report from the Biochemistry Laboratory, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Wolf, G.L. and Fassett, D.W., (1968a), Electron microscope study of livers of rats, fed monotertiary butyl hydroquinone. Unpublished report from the Laboratory of Industrial Medicine, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Wolf, G.L. and Fassett, D.W., (1968b), Electron microscope study of livers of dogs fed monotertiary butyl hydroquinone for two years. Unpublished report from the Laboratory of Industrial Medicine, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.



Fassett, D.W., Roudabush, R.L. and Terhaar, C.J., (1965), Reproduction study on rats fed monotertiary butyl hydroquinone. Unpublished report of the Eastman Kodak Company, dated 20 May, 1965.

Krasavage, W.J., (1977), Evaluation of the Teratogenic Potential of Tertiary Butyl Hydroquinone (TBHQ) in the Rat. *Teratology*, 16 (1), 31-34.

Wolf, G.L. and Fassett, D.W., (1968), Electron Microscope Study of Livers of Rats fed Monotertiary Butyl Hydroquinone. Unpublished report of the Eastman Kodak Company, dated 3 April, 1968.

IPL (Institut Pasteur de Lille), (1982a), Unpublished report IPL-R 82044 submitted by Société Kemina France.

IPL (Institut Pasteur de Lille), (1982b), Unpublished report IPL-R 82050 submitted by Société Kemina France.

CERTI (Cabinet d'Etudes et de Recherches en Toxicologie Industrielle), (1982), Unpublished report Etude No. 678, submitted by Kemina Europe NV, Belgium.

Flamm, W.G. et al., (1982), Report of the working group on the toxicology and metabolisms of antioxidants on TBHQ, October 1984.

Litton Bionetics Inc., (1982a), Mutagenicity evaluation of EK 81-0318 (TBHQ) in the mouse micronucleus test. Eastman Kodak Co. NY (unpublished report LBI Project No. 20996).

Litton Bionetics Inc., (1982b), Mutagenicity evaluation of EK-81-0318 (TBHQ) in the mouse lymphoma forward mutation assay. Submitted by Eastman Kodak Co. NY (unpublished report LBI Project No. 20989).

Krasavage, W.J. and Faber, W.D., (1983), Tertiary butylhydroquinone (TBHQ) : dominant lethal assay in rats. Health, Safety and Human Factors Laboratory, Eastman Kodak Co. NY (unpublished report, April 20).

Mueller, K.R., (1983), Effects of butylated hydroxytoluene and tertiary butylhydroquinone on respiratory chain phosphorylation in isolated rat liver mitochondria. Health, Safety and Human Factors Laboratory, Eastman Kodak Co. NY (unpublished report, March 25).

Mueller, K.R. and Lockhart, H.B., Jr., (1983), In vitro genetic activity report : evaluation of mono-tertiary butyl hydroquinone in the Ames Salmonella/microsome bacterial mutagenesis test. Health, Safety and Human Factors Laboratory, submitted by Eastman Kodak Co. NY (unpublished report, March 25, 1983).

OEZFS (Österreichisches Forschungszentrum Selbersdorf), (1983), Unpublished report No. A0372 BL-406/83. The influence of TBHQ on DNA metabolism in spleen cells. Submitted by Kemin Europe NV, Belgium.

Giri, A.K., San, S., Talukdar, G., Sharma, A. and Banerjas, T.S., (1984), Mutachromosomal effects of tert-butyl hydroquinone in bone-marrow cells of mice. *Fd. Chem. Tox.*, 22 (6), 459-460.

Krasavage, W.J., (1984), The lack of effect of tertiary butylhydroquinone on prothrombin time in male rats. *Drug Chem. Toxicol.*, 7 (4), 329-334.

Krasavage, W.J. and O'Donoghue, J.L., (1984), Lack of lung damage in mice following administration of tertiary butylhydroquinone. *Drug Chem. Toxicol.*, 7 (4), 335-343.

Report of Eastman Chem. International AG, Summary of additional studies on TBHQ (EEC No CS/TBHQ/8).

#### Additional References

Heimann, W. and von Pezold, H., (1957), Über die prooxygene Wirkung von Antioxygenen. *Fette Seifen Anstrichmittel*, 59, 330.

Report of the Joint FAO/WHO Expert Committee on Food Additives, (1975), WHO, Techn. Rep. Series No. 8, page 65-79.

Astill, B.D. and Mulligan, L.T., (1977), Phenolic antioxidants and the inhibition of hepatotoxicity from N-dimethylnitrosamine formed in situ in the rat stomach. *Food Cosmetic. Toxicol.*, 15, 167-171.

Boehme, M.A. and Branen, A.L., (1977), Effects of food antioxidants on prostaglandine biosynthesis. *J. Food Sci.*, 42, 1243-1246, 1250.

2nd Series of Reports of the Scientific Committee for Food, (1976).

Twenty-first report of the Joint FAO/WHO Expert Committee on Food Additives (1978), WHO, Techn. Rep. Series No. 617.

Logani, M.K. and Davies, R.E., (1979), Lipid oxidation : Biologic effects and antioxidants. A review. *Lipids*, 15, 485.

Shamberger, R.J., Corlett, C.L., Beaman, K.D. and Kasten, B.L., (1979), Antioxidants reduce the mutagenic effect of malonaldehyde and beta-propiolactone. *Mut. Res.*, 66, 349.

Van Dokkum, W. et al., (1982), Food additives and food components in total diets in the Netherlands. *Br. J. Nutr.*, 48, 223.

Kurechi, T. and Kato, T., (1983), Studies on the antioxidants. XX. The effect of butylated hydroxytoluene on tert-butylhydroperoxide-induced oxidation of butylated hydroxytoluene on tert-butylhydroperoxide-induced oxidation of butylated hydroxyanisole. *Chem. Pharm. Cull.*, 31, 1772.

Simic, M.G. and Hunter, E.P.L., (1983), Interaction of free radicals and antioxidants in : Nygaard, O.F., Simic, M.G. and Hauber, J.N. (eds.) *Radioprotectors and Anticarcinogens*, p. 449, Academic Press, New York.

14th Series of Reports of the Scientific Committee for Food, (1984), EUR 8752.

EEC No CS/TBHQ/7.

III/905/EEC/84.

Report of an ad hoc working group on the safety of antioxidants of the EEC, (December 1984), No III/1682/84.

Kappus, H., (1985), Lipid peroxidation : Mechanisms, analysis, enzymology and biological relevance, in : H. Sies (ed.) *Oxidative Stress*, p. 273, Academic Press, New York.

MacGregor, J.T., Wilson, R.E., Neff, W.E. and Frankel, E.N., (1985), Mutagenicity tests of lipid peroxidation products in *Salmonella typhimurium* : Monohydroperoxides and secondary peroxidation products of methyl linoleate and methyl linoleate. *Food Chem. Toxicol.*, 23, 1041.

McCay, P.B., (1985), Vitamin E : Interactions with free radicals and ascorbate. *Ann. Rev. Nutr.*, 5, 323.

Sevanian, A. and Hochstein, P., (1985), Mechanisms and consequences of lipid peroxidation in biological systems. *Ann. Rev. Nutr.*, 5, 365.



European Communities — Commission

**EUR 12535 — Reports of the Scientific Committee for Food**  
(Twenty-second series)

Luxembourg: Office for Official Publications of the European Communities

1990 — IV, 61 pp. — 21.0 × 29.7 cm

Food — Science and techniques series

ES, DA, DE, GR, EN, FR, IT, NL, PT

ISBN 92-826-1070-5

Catalogue number: CD-NA-12535-EN-C

Price (excluding VAT) in Luxembourg: ECU 6.25

The Scientific Committee for Food was established by Commission Decision 74/234/EEC of 16 April 1974 (OJ L 136, 20.5.1974, p. 1) to advise the Commission on any problem relating to the protection of the health and safety of persons arising from the consumption of food, and in particular the composition of food, processes which are liable to modify food, the use of food additives and other processing aids as well as the presence of contaminants.

The members are independent persons, highly qualified in the fields associated with medicine, nutrition, toxicology, biology, chemistry, or other similar disciplines.

The Secretariat of the Committee is provided by the Directorate-General for Internal Market and Industrial Affairs of the Commission. Recent Council directives require the Commission to consult the Committee on provisions which may have an effect on public health falling within the scope of these directives.

The present report relates to the opinion of the Scientific Committee for Food on the safety of antioxidants.



**Venta y suscripciones • Salg og abonnement • Verkauf und Abonnement • Πωλήσεις και συνδρομές  
Sales and subscriptions • Vente et abonnements • Vendita e abbonamenti  
Verkoop en abonnementen • Venda e assinaturas**

**BELGIQUE / BELGIË**

**Moniteur belge / Belgisch Staatsblad**

Rue de Louvain 42 / Louvenseweg 42  
1000 Bruxelles / 1000 Brussel  
Tél. (02) 512 00 26  
Fax 511 01 84  
CCP / Postrekening 000-2005502-27

Autres distributeurs / Overige verkooppunten

**Librairie européenne /  
Europese Boekhandel**

Avenue Albert Jonnart 50 /  
Albert Jonnartlaan 50  
1200 Bruxelles / 1200 Brussel  
Tél. (02) 734 02 81  
Fax 735 08 60

**Jean De Lanoy**

Avenue du Roi 202 / Koningslaan 202  
1060 Bruxelles / 1060 Brussel  
Tél. (02) 538 51 69  
Télex 63220 UNBOOK B

**CREDOC**

Rue de la Montagne 34 / Bergstraat 34  
Bte 11 / Bus 11  
1000 Bruxelles / 1000 Brussel

**DANMARK**

**J. H. Schultz Information A/S  
EF-Publikationer**

Ottliavej 18  
2500 Valby  
Tlf. 36 44 22 66  
Fax 36 44 01 41  
Girokonto 6 00 08 86

**BR DEUTSCHLAND**

**Bundesanzeiger Verlag**

Breite Straße  
Postfach 10 80 06  
5000 Köln 1  
Tel. (0221) 20 29-0  
Fernschreiber:  
ANZEIGER BONN 8 882 595  
Fax 20 29 278

**GREECE**

**G.C. Eleftheroudakis SA**

International Bookstore  
Nikis Street 4  
10563 Athens  
Tel. (01) 322 63 23  
Telex 219410 ELEF  
Fax 323 98 21

**ESPANA**

**Boletín Oficial del Estado**

Trafalgar, 27  
28010 Madrid  
Tel. (91) 446 60 00

**Mundi-Prensa Libros, S.A.**

Castelló, 37  
28001 Madrid  
Tel. (91) 431 33 99 (Libros)  
431 32 22 (Suscripciones)  
435 36 37 (Dirección)  
Télex 49370-MPLI-E  
Fax (91) 275 39 98

Sucursal:

**Librería Internacional AEDOS**

Consejo de Ciento, 391  
08009 Barcelona  
Tel. (93) 301 86 15  
Fax (93) 317 01 41

Generalitat de Catalunya:

**Llibreria Rambla dels estudis**

Rambla, 118 (Palau Moja)  
08002 Barcelona  
Tel. (93) 302 68 35  
302 64 62

**FRANCE**

**Journal officiel  
Service des publications  
des Communautés européennes**

26, rue Desaix  
75727 Paris Cedex 15  
Tél. (1) 40 58 75 00  
Fax (1) 40 58 75 74

**IRELAND**

**Government Publications Sales Office**

Sun Alliance House  
Molesworth Street  
Dublin 2  
Tel. 71 03 09

or by post

**Government Stationery Office**

**EEC Section**

6th floor  
Bishop Street  
Dublin 8  
Tel. 78 16 66  
Fax 78 06 45

**ITALIA**

**Licosa Spa**

Via Benedetto Fortini, 120/10  
Casella postale 552  
50125 Firenze  
Tel. (055) 64 54 15  
Fax 64 12 57  
Telex 570466 LICOSA I  
CCP 343 509

Subagenti:

**Libreria scientifica Lucio de Biasio - AEIOU**

Via Meravigli, 16  
20123 Milano  
Tel. (02) 80 76 79

**Herder Editrice e Libreria**

Piazza Montecitorio, 117-120  
00186 Roma  
Tel. (06) 679 46 28 679 53 04

**Libreria giuridica**

Via 12 Ottobre, 172/R  
16121 Genova  
Tel. (010) 59 56 93

**GRAND-DUCHÉ DE LUXEMBOURG**

Abonnements seulement  
Subscriptions only  
Nur für Abonnements

**Messageries Paul Kraus**

11, rue Christophe Plantin  
2339 Luxembourg  
Tél. 499 88 88  
Télex 2515  
CCP 49242 63

**NEDERLAND**

**SDU uitgeverij**

Christoffel Plantijnstraat 2  
Postbus 20014  
2500 EA 's-Gravenhage  
Tel. (070) 78 98 80 (bestellingen)  
Fax (070) 47 63 51

**PORTUGAL**

**Imprensa Nacional**

Casa da Moeda, EP  
Rua D. Francisco Manuel de Melo, 5  
1092 Lisboa Codex  
Tel. (01) 69 34 14

**Distribuidora de Livros Bertrand, Ld.ª**

**Grupo Bertrand, SARL**

Rua das Terras dos Vales, 4 A  
Apartado 37  
2700 Amadora Codex  
Tel. (01) 493 90 50 494 87 88  
Telex 15798 BERDIS  
Fax 491 02 55

**UNITED KINGDOM**

**HMSO Books (PC 16)**

HMSO Publications Centre  
51 Nine Elms Lane  
London SW8 5DR  
Tel. (01) 873 9090  
Fax GP3 873 8463

Sub-agent:

**Alan Armstrong Ltd**

2 Arkwright Road  
Reading, Berks RG2 0SQ  
Tel. (0734) 75 18 55  
Telex 849937 AAALTD G  
Fax (0734) 75 51 64

**SCHWEIZ / SUISSE / SVIZZERA**

**OSEC**

Stampfenbachstraße 85  
8035 Zurich  
Tel. (01) 365 51 51  
Fax (01) 365 52 21

**ÖSTERREICH**

**Manz'sche Verlags-  
und Universitätsbuchhandlung**

Kohlmarkt 16  
1014 Wien  
Tel. (0222) 531 61-0  
Telex 11 25 00 BOX A  
Fax (0222) 531 61-81

**TURK YE**

**Dünya süper veb ofset A.Ş.**

Narlıbahçe Sokak No. 15  
Cağaloğlu  
Istanbul  
Tel. 512 01 90  
Telex 23822 DSVO-TR

**UNITED STATES OF AMERICA**

**UNIPUB**

4611-F Assemb y Drive  
Lanham, MD 20706-4391  
Te. To Free 800 274 4888  
Fax (301) 459 0056  
Te ex 7108260418

**CANADA**

**Renouf Publishing Co., Ltd**

61 Sparks Street  
Ottawa  
Ontario K1P 5R1  
Te To Free 1 800 267 41 64  
Ottawa Reg on 613) 238 89 85-6  
Telex 053-4936

**JAPAN**

**Kinokuniya Company Ltd**

17-7 Shinjuku 3-Chome  
Shinjuku ku  
Tokyo 160-91  
Te. (03) 354 01 31

**Journal Department**

PO Box 55 Chitose  
Tokyo 156  
Te. (03) 439 01 24

**SVERIGE**

**BTJ**


Box 200  
22100 Lund  
Te. (046) 18 00 00  
Fax (046) 18 C1 25

**AUTRES PAYS**

**OTHER COUNTRIES  
ANDERE LANDER**

**Office des publications officielles  
des Communautés européennes**

2, rue Mercier  
L-2985 Luxembourg  
Tél. 49 92 81  
Télex PUBOF LU 1324 b  
Fax 48 85 73  
CC bancaire BIL 8 109 6003/700



## NOTICE TO THE READER

All scientific and technical reports published by the Commission of the European Communities are announced in the monthly periodical '**euro abstracts**'. For subscription (1 year: ECU 76.50) please write to the address below.

---

Price (excluding VAT) in Luxembourg: ECU 6.25

ISBN 92-826-1070-5



OFFICE FOR OFFICIAL PUBLICATIONS  
OF THE EUROPEAN COMMUNITIES

L-2985 Luxembourg



9 789282 610701